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ABSTRACT 
 
Lung cancer is the commonest cancer in Scotland and survival rates for 
patients in Scotland appear lower than in many other European countries. 
Although this variation in survival is usually interpreted as evidence of 
variation in facilities, access to care and clinical practice it is possible that 
the increased comorbidity and poor performance status of the Scottish 
population may contribute to the observed disparities in treatment and 
outcomes, although this has never been proven. 
 
The overall aim of the Thesis was to examine the impact of comorbidity in 
lung cancer, to attempt to quantify the extent and severity of comorbidity 
and to explore its relationship with treatment and survival. 
 
Between 2005 and 2008 all newly diagnosed lung cancer patients coming 
through the Multi-Disciplinary Teams (MDTs) in four Scottish Centres were 
included in the study. Patient demographics, World Health 
Organization/Eastern Cooperative Oncology Group performance status 
(PS), clinic-pathological features, stage, comorbidity, markers of systemic 
inflammation and proposed primary treatment modality were all recorded.  
Information on date of death was obtained via survival analysis undertaken 
by the Information Service Division (ISD) of NHS Scotland. Death records 
were complete until 1 June 2011, which served as the censor date for 
those alive. 
 
Chapter 4 examines the variations in demographics and baseline 
characteristics seen between the centres and reveals significant 
differences between the centres such as deprivation, stage at 
presentation, PS and treatments offered.  
 
Chapter 5 explores the relationship between comorbidity and the patient 
cohort. It shows that comorbidity can be quantified using a scoring index 
(the Scottish Comorbidity Scoring System (SCSS)) and that increasing 
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comorbidity is associated with treatment centre and socio-economic 
status, with the most deprived patients having increased levels of co-
morbidity. It also demonstrates that comorbidity appears to have an 
impact on treatment offered.  
 
Chapter 6 examines the relationship between systemic inflammation 
(utilizing the well established modified Glasgow Prognostic Score (mGPS)) 
and outcome in the patient cohort. It confirms previous work supporting 
the use of the mGPS in predicting lung cancer survival and also shows how 
it might be used to provide more objective risk stratification in patients 
diagnosed with lung cancer. 
 
Chapter 7 explores the relationship between a novel comorbidity scoring 
system (SCSS) and the already established Charlson Comorbidity Index 
(CCI) and the modified Glasgow Prognostic Score (mGPS). This study aimed 
to determine which of these factors provided the most accurate 
information on survival. The novel comorbidity scoring system, the SCSS 
compares very favourably with the more established CCI. In addition this 
study demonstrates clear differences between patients having potentially 
radically treatable disease (NSCLC stage I – IIIa) and disease which would 
generally be considered incurable (NSCLC IIIb/IV and SCLC).   
 
Chapter 8 examines the reasons for the clinician decision-making process 
and if these reasons do indeed mirror the individual patient’s 
demographics, fitness and stage. In the majority of patients, both in the 
early and advanced stage at presentation, the treatment decision appears 
to be appropriate given the recorded fitness, PS and comorbidity. However 
in a small but significant number of patients there did appear to be 
discrepancies between the clinician’s reasons for sub-optimal therapy and 
the recorded objective assessment of the patient in question. 
 
The work presented in this thesis has demonstrated the significant extent 
of comorbidity in lung cancer and the important role it appears to play 
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(along with systemic inflammation) in determining treatment choice and 
survival. 
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CHAPTER 1: INTRODUCTION 
 
 
1.1 Lung Cancer in Scotland 
 
 
Lung cancer is the commonest cancer in Scotland and the second 
commonest in the UK (Office for National Statistics, 2006; ISD, 2009). In 
2011 5,096 cases of lung cancer were recorded in Scotland.  2,601 were in 
males with 2,495 being in females. The incidence rate in Scotland was 
97.0 per 100,000 in comparison to 68.7 per 100,000 across the UK (ISD 
Scotland, 2013).  The incidence rates in Scotland remain amongst the 
highest in the world (Parkin et al., 2002) reflecting the history of high 
smoking prevalence. 
 
Treatment and survival rates for patients with lung cancer in Scotland 
appear lower than in many other European countries. Five-year survival is 
quoted at 6-7% (Gregor et al., 2001) compared with 8-15% in other 
European countries and America (Janssen-Heijnen et al., 1998). Erridge et 
al showed significant differences in survival between Scotland and British 
Columbia with 2 yr. OS being 10% vs. 23% (Erridge et al., 2009). There also 
appear to be variations in treatment rates within Scotland (Gregor et al., 
2001). 
 
Although this variation in treatment and survival is usually interpreted as 
evidence of variation in facilities, access to care and clinical practice it is 
possible that the increased co-morbidity and poor performance status of 
the Scottish population may contribute to the observed disparities in 
treatment and outcomes, although this has never been proven. In a recent 
Lung Cancer paper Erridge et al suggesting that suboptimal treatment is 
not the only reason for poor outcome, even when treatment rates were 
taken into account, also showed a significant hazard ratio for death of 1.5.  
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The majority of patients with lung cancer will have smoked and will, in 
general, have a less favourable socio-economic status, two factors known 
to be associated with an increased likelihood of co-morbid conditions e.g. 
Chronic Obstructive Pulmonary Disease (COPD), Ischaemic Heart Disease, 
that influence treatment options. Co-existent comorbidities may also have 
an adverse effect on the rate of deterioration of performance status when 
lung cancer develops, with obvious consequence for treatment options and 
survival. The demonstration that comorbidity influences treatment and 
survival rates will have important implications for the targeting of health 
services resources, screening, interpretation of cancer statistics and the 
assessment and management of patients with lung cancer. 
 
 
1.2 Incidence 
 
 
Lung cancer incidence is strongly related to age. In the UK more than four 
in ten cases are in those aged 75+ (Office for National Statistics, 2013; ISD 
Scotland, 2013). 
 
Male lung cancer incidence rates have gradually decreased over the last 
twenty years. Unfortunately the rates for females continue to rise 
indicating the changing frequency of smoking between the sexes (Office 
for National Statistics, 2013;ISD, 2013) 
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Figure 1.1 European Age-Standardised Incidence Rates per 100,000 
Population, by Sex, Great Britain 
 
 
 
 
 
 
 
There also appears to be an association between lung cancer incidence 
and deprivation. Data from England in 2006 -2010 shows significantly 
higher rates for those living in the most deprived areas compared to the 
least (CRUK, 2012). 
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Figure 1.2 European Age-Standardised Incidence Rates by 
Deprivation Quintile, England 
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1.3 Lung cancer risk factors 
 
Smoking remains the commonest cause of lung cancer with an estimated 
86% of lung cancer deaths in the UK being caused by tobacco smoking 
(Parkin et al., 2011). In addition lung cancer death risk is around 15 times 
higher in current smokers compared with never-smokers. (Doll et al., 
2005) 
 
An estimated 0.5% of lung cancer in the UK is linked to radon gas 
exposure.  (Parkin et al., 2011). Approximately 1% of the total is linked to 
previous radiation exposure (either radiotherapy or diagnostic radiation) 
(Parkin et al., 2011) 
 
A number of occupational exposures are classified as causes of lung 
cancer. This is seen in an estimated 21% of men with lung cancer and 5% of 
women. This is commonest in occupations linked to asbestos exposure 
(typically construction and shipyard workers) with an estimated 6-8% of all 
lung cancer in the UK being associated with asbestos exposure. (Brown et 
al., 2012). 
 
Lung cancer risk is increased in survivors of several cancers. In particularly 
previous breast cancer (Lorigan et al., 2010; Maddams et al 2011) and 
Hodgkin’s lymphoma (Ibrahim et al., 2013). This risk is related to previous 
thoracic radiotherapy.  
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1.4 Presentation 
 
 
Lung cancer often produces very few symptoms until the disease is well 
advanced (over 50% will have incurable disease at diagnosis (NLCA, 2013). 
In addition lung cancer can present as an incidental finding on chest 
radiological imaging undertaken for other reasons. (Spiro et al., 2007). 
When lung cancer presents in this way it is more often diagnosed at an 
early and potentially curable stage). 
 
Cough is the most commonly reported symptom along with dyspnoea, 
chest pain and haempotysis due to chest disease. Non-specific symptoms 
such as weight loss, fatigue and cachexia are commonly seen due to 
metastatic disease. Specific symptoms due to site of metastatic spread 
such as headaches with intracranial deposits and localised pain due to 
bone metastasis are also commonly seen. 
 
 
1.5 Diagnosis 
 
 
A chest x-ray is the first investigation for all patients being investigated 
for the possibility of lung cancer (Detterbeck et al., 2001). A contrast 
enhanced CT scan of the chest and abdomen is recommended in all 
suspected lung cancer cases, regardless of CXR findings (SIGN 137). Results 
from CT scanning are variable but a high sensitivity and relatively lower 
specificity is the norm (Yankelevitz et al., 1999).  This should be 
performed prior to further diagnostic investigation, including 
bronchoscopy, as the result of the CT scan is likely to help guide the 
investigation most likely to provide a diagnosis (Laroche et al., 2000). 
 
If not contraindicated either by patient fitness or wishes then a tissue 
diagnosis should be obtained both to confirm diagnosis and help determine 
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most appropriate treatment (SIGN 137). Bronchoscopy has a good 
diagnostic sensitivity for central lesions (Schreiber et al., 2003). However 
this is lower for peripheral lesions (Schreiber et al., 2003) in which case 
percutaneous biopsy should be considered (Detterbeck et al., 2001). 
 
All pathological samples should be, if possible, classified as Small Cell 
Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC). NSCLC tumours 
should then be subtyped and genetic mutations for EGFR and ALK 
examined for (SIGN 137). 
 
 
1.6 Staging 
 
Lung cancer is currently staged using the 7th edition of TNM staging 
system, which covers NSCLC and SCLC. At the time of data collection of 
this research the 6th edition of TNM was the current version and for all 
future references during this work it will be the 6thedition, which will be 
used. It is to be acknowledged that the TNM staging update, in particular 
the refined use of tumour size, may make a potential difference to 
interpretation of the results. However the data recorded would not allow 
for formal “restaging” of patients. 
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Table 1.1 International Lung Cancer Staging (6th edition) 
 
T1 ≤3cm, surrounded by lung or visceral pleura, without bronchscopic evidence of 
invasion of more proximal than lobar bronchus 
 
T2 Any of the following features: 
≥3cm 
involves main bronchus, 2cm or more distal to the carina 
invades visceral pleura 
associated with atelectasis or obstructive pneumonitis that extends to the hilar 
region but does not involve the entire lung 
 
T3 Tumour of any size that directly invades any of the following: 
chest wall 
diaphragm 
mediastinal pleura 
parietal pericardium 
tumour in main bronchus <2cm distal to carina 
associated with atelectasis or obstructive pneumonitis that involves the entire 
lung 
 
T4 Tumour of any size that invades any of the following: 
mediastinum 
heart 
great vessels 
trachea 
oesophagus 
vertebral bod 
carina 
 
Or separate tumour nodules in the same lobe 
Or tumour with malignant pleural effusion 
 
N0  No involved lymph nodes. 
N1  Involved ipsilateralhilar lymph nodes. 
 
N2  Involved mediastinal lymph nodes. 
 
N3  
 
Involved contralateral lymph nodes. 
 
 
M1 Distant metastasis present 
T = Primary tumour, N = Regional Lymph Nodes, M = Distant Metastasis 
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Table 1.2 Stage Grouping 
 
Stage T N M 
 
Ia T1 
 
Ib T2 
 
IIa T1 N1 
 
IIb T2 N1 or T3 N0 
 
IIIa T1 N2, T2 N2, T3 N1 or T3 N2 
 
IIIb Any T4 or any N3 
 
IV Any M1 
 
 
 
CT scanning is poor at predicting more advanced T staging e.g. T3/4 
(Detterbeck et al., 2001). FDG PET-CT is more accurate in detecting 
mediastinal nodal metastases in patients with NSCLC (De Leyn et al., 
2007). In addition FDG PET-CT has been shown to identify unsuspected 
metastases in 10-15% of patients with NSCLC (Pieterman et al., 2000). As 
such, all patients with NSCLC being considered for radical treatment 
should have a staging FDG PET-CT. 
 
The majority of patients have advanced stage disease (NSCLC IIIb/IV or 
SCLC) at time of diagnosis (national lung cancer audit report 2012). In the 
most recent national lung cancer audit 12% of new lung cancer cases were 
classified as SCLC. The remaining cases were either NSCLC (87%) or 
carcinoid (1%). Of the different subtypes of NSCLC squamous (35%) and 
adenocarcinoma (30-40%) are the most common. 
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1.7 Treatment of NSCLC 
 
Treatment options are dependent upon pathology, TNM staging, patient 
fitness and choice. Radical (i.e. potentially curable) treatment options are 
surgery or radical radiotherapy (+/- chemotherapy). 
 
Surgery 
 
Patients with Stage I + II NSCLC should be considered for curative surgery 
whenever possible as it confers the highest chance of cure. 5 Year survival 
of 54-80% for patients with St 1a and 38-65% for patients with Stage 1b has 
been reported (Suzuki et al., 1999; Makitaro et al., 2002; Inoue et al., 
1998). In patients with good performance status (PS 0/1) that have 
completely resected NSCLC (stage II to IIIa) should be offered platinum 
based postoperative systemic anticancer therapy (NSCLC Meta-analyses 
Collaborative Group. 2010). 
 
Radical Radiotherapy 
 
In patients with localized NSCLC not fit / suitable for surgery, radical 
radiotherapy (+/- chemotherapy) is an appropriate option. Meta-analysis 
of retrospective studies in patients with Stage I/II has shown overall 
survival from 50-93% at one year and 0-42% at 5 years (Rowell et al., 
2004). In recent years the option of Stereotactic Ablative Radiotherapy has 
become a very reasonable alternative for those with early stage disease 
and in many institutions has replaced conventional radiotherapy in this 
setting. (Palma et al., 2011; Lagerwald FJ., 2012) 
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Palliative Chemotherapy 
 
In patients with advanced disease and a PS <2 then systemic chemotherapy 
with a platinum based doublet has been shown to confer a survival benefit 
of approximately 2 – 4 months (Goffin et al., 2010). Recent advances 
including tyrosine kinase inhibitors (in those with an EGFR mutation) 
(Rosell et al., 2012) and pemetrexed/platinum doublets in 
adenocarcinoma (Scagliotti et al., 2008) have shown further improvement 
in survival but these treatments were not routinely available at the time 
of this research. 
 
Symptomatic Therapy 
 
Palliative radiotherapy to areas causing symptoms such as pain is very 
effective at reducing such symptoms. In addition all patients should be 
considered for referral to specialist palliative care services (SIGN  137). 
There has also been some suggestion of a modest improvement in survival 
with early integrated palliative care input (Temel et al., 2010) 
 
 
1.8 Treatment of SCLC 
 
Limited disease SCLC 
 
Systemic chemotherapy with a platinum based doublet in patients of good 
PS has been shown to confer a survival benefit over single agent therapy 
(Simon et al., 2003). Radiotherapy delivered either concurrently or 
sequentially to the primary site appears to derive a benefit in survival, 
although absolute figures are difficult to quantify (De Ruysscher et al., 
2000). In patients who have achieved remission after systemic 
chemotherapy, prophylactic cranial irradiation should be considered as it 
has been shown to confer a survival benefit (Arrigada et al., 2002; Auperin 
et al., 1999). 
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However even with optimal combination therapy two year survival is only 
around 25% (SIGN) 
 
Extensive disease SCLC 
 
Durable responses to chemotherapy are seldom seen. However there is 
often a useful symptomatic response (Girling. 1996).  
 
1.9 Mortality 
 
Lung cancer accounts for 6% of all deaths in the UK and is also the 
commonest cause of cancer death in the UK (2011), accounting for 22% of 
all cancer deaths. It is the commonest cause of death for both males (23%) 
and females (21%). Lung cancer is also the most common cause of cancer 
death worldwide, with around 1,590,000 deaths from lung cancer in 2012 
(19% total) (Office for National statistics, 2012). 
 
In Scotland there were 4,178 deaths due to lung cancer in 2011. 2,200 
deaths were in males with 1,978 in females. The European age-
standardised mortality rates (AS rates) are significantly higher in Scotland 
compared with the remainder of the UK. In Scotland they are 53.1 / 
100,000 compared to 38.2 / 100,000 for the UK (ISD Scotland, 2013). 
 
Data from the UK also appears to show an association between mortality 
and deprivation with European AS rates being approximately 170% higher 
in those living in the most deprived areas compared to the least deprived 
(CRUK, 2013). 
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Figure 1.3 European Age-Standardised Mortality Rates by 
Deprivation Quintile, England 
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1.10 Survival 
 
 
Lung cancer has one of the lowest survival outcomes of any cancer 
because the majority of patients are diagnosed when the disease is 
already advanced and there is no curative option. In addition, the majority 
of patients are older (approx. 70 years) and have high incidence of co 
morbidities (NLCA Report, 2005).  
 
Current 1 year survival in England is 29.4% for men and 33% in woman. This 
falls to 7.8% for men and 9.3% at 5 years respectively (Office National 
Statistics, 2010; ISD, 2011). 
 
Table 1.3 Age-Standardised One, Five and Ten Year Relative Survival 
Rates, Adults Aged 15-99, England 2005-2009, England and Wales 2007 
 
  Relative Survival (%) 
1 Year 5 Year 10 Year 
Sex 2005-2009 2005-2009* 2007** 
Male 29.4 7.8 4.9 
Female 33 9.3 5.9 
 
 
By age 
 
Lung cancer survival has been show to worsen as age increases for both 
men and women. For example five-year relative survival rates for men in 
England during 2005-2009 ranged from 35% in those diagnosed before 40 to 
3% in those over 80. 
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By Stage 
 
The majority of patients are diagnosed at an advanced stage with two 
thirds of NSCLC having either stage IIIb / IV (ISD Scotland). One and five 
year survival is strongly linked to stage at diagnosis. In NSCLC the one year 
survival varied from 71% in patients with stage I to 14% in those with stage 
IV. Five year survival was 35% and 1% respectively. 
 
 
 
Figure 1.4 One-Year Relative Survival (%) by Stage, Adults 15-99, 
Former Anglia Cancer Network 
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Figure 1.5 Five-Year Relative Survival (%) by Stage, Adults 15-99, 
Former Anglia Cancer Network 
 
 
By Deprivation 
 
Analyses of lung cancer survival rates by socio-economic status in England 
and Wales in the late 1990s has shown a small but significant difference of 
1.4% between men in the most and least affluent groups (Coleman et al., 
2004). 
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Lung cancer is the commonest cancer in Scotland and survival rates for 
patients in Scotland appear lower than in many other European countries. 
Although this variation in survival is usually interpreted as evidence of 
variation in facilities, access to care and clinical practice it is possible that 
the increased comorbidity and poor performance status of the Scottish 
population may contribute to the observed disparities in treatment and 
outcomes, although this has never been proven. 
 
The overall aim of the Thesis was to examine the impact of comorbidity in 
lung cancer, to attempt to quantify the extent and severity of comorbidity 
and to explore its relationship with treatment and survival. 
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CHAPTER 2: REVIEW OF THE LITERATURE 
 
 
2.1 Materials and Methods 
 
Literature searches were undertaken via PubMed and Google Scholar using 
various arrays of the following keywords; Cancer, Comorbidity, Lung 
Cancer, Performance Status, Survival and Tools. The search was limited to 
published articles in peer-review journals with English as the language. No 
Abstract or posters were included in the review. Results were separated 
into several sections. Tools available to assess comorbidity, association 
between comorbidity and outcome and finally the impact upon survival. 
The search was completed in March 2010. An extension of the literature 
review to include up until December 2015 and how recent papers relate to 
the work in this thesis is presented in Chapter 9. 
 
 
2.2 Tools available to assess co-morbidity in cancer 
 
The evaluation of comorbidity in Lung Cancer is a relatively new area of 
research. In recent years a number of studies have attempted to assess 
the impact of comorbidity, performance status and age on treatment and 
survival in lung cancer. A variety of tools have been used to quantify co-
morbidity primarily in breast and prostate cancer (Extermann. 2000) 
although none of these have been validated in lung cancer. In addition the 
majority of lung cancer patients are from lower socio-economic classes 
with significant factors which may influence ability to deliver curative 
treatment e.g. Chronic Obstructive Pulmonary Disease and Ischaemic 
Heart Disease. The biology of lung cancer is obviously significantly 
different from the afore-mentioned tumour types in terms of treatment 
options, stage at time of presentation and median survival. 
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Extermann reviewed 4 tools currently in place. Although these have all 
been validated against cancer outcomes, none have been specifically 
validated in lung cancer.  
 
The most widely quoted tool is the Charlson Comorbidity Index (Charlson 
et al., 1987) (CCI). This was designed in 1987 and assigned 19 conditions 
with a weighting index of 1 – 6 in attempt to quantify the likelihood of 
impact upon survival. Data was acquired via patients being admitted with 
medical conditions to a Washington Hospital. This tool was initially 
validated in breast cancer patients with 10-year mortality as an endpoint. 
It has also been validated in predicting progression-free survival (Chen et 
al., 1999) in a variety of diseases such as breast and prostate cancer. 
However limitations with using this tool for lung cancer patients include 
absence of some potentially relevant diseases such as pulmonary fibrosis, 
the weighting of HIV is probably now less significant due to improved 
treatment and the lack of grading of severity of the specific disease(s). 
 
The second method reviewed was the Cumulative Illness Rating Scale 
(CIRS). Designed in 1968 by Linn et al, this scale scores 14 organ systems 
with severity between 0-4. Since its conception it has been modified on a 
number of occasions and recently modified to cirs-geriatric that is 
specifically designed to assess geriatric oncology patients. It has been 
validated previously in elderly cancer patients using mortality rates as an 
end-point. Due to the large number of comorbidities it becomes more 
unwieldy and therefore has not been used widely in clinical practice. 
There is no published validation of the CIRS in lung cancer. 
 
The Index of Coexistent Disease (ICED) was developed by Greenfield et al 
in 1987. Two subscales attempt to measure physical and functional co-
morbid status. The physical subscale incorporates 14 categories with grade 
of severity 0-4. The functional subscale has 12 domains each rated 0-2. 
Overall severity is then summarised 0-3. This is the first such system to 
attempt to gain an understanding of the functional impact of comorbidity 
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rather than relying on physiological results and as such has much to 
recommend it. The ICED has been used in cancer studies with good 
validation but not in lung cancer (Bennett et al., 1991; Guadagnoli et al., 
1997) In addition this is a very complicated system and it is unlikely that 
the information could easily be collected at the time of the decision 
making process. Thus its greatest attribute is possibly its major failing. 
 
The Kaplan-Feinstein Index (Kaplan et al., 1974) was developed in 1974 
and comprises 12 categories graded 0-3. It has been shown to be 
predictive of outcome in prostate and head and neck cancer (Clemens et 
al., 1986; Piccirillo, 1995) but not validated in lung cancer.  
 
A more recent tool validated in head and neck cancer patients was the 
Adult Co-morbidity Evaluation 27 (ACE-27) (Piccirillo et al., 2004). This 
graded 27 specific conditions from mild to severe. A prospective cohort 
study including over 17,000 patients with all major cancer types was 
undertaken. This showed that worsening comorbidity significantly 
impacted negatively on survival. Unfortunately sub-group analysis 
identified comorbidity as having least prognostic information in lung 
cancer patients. A clear reason for this was not identified. It may be 
related to the finding that comorbidity had greatest impact on survival in 
indolent cancers with long survival time. This is an interesting view point 
but fails to address the affect that comorbidity has upon ability to deliver 
radical treatment. 
 
The simplest tool, superficially at least, is the American Society of 
Anesthesiologists (ASA), which initially used a five-category physical status 
classification system; a sixth category was later added (ASA Relative value 
Guide. 2002). This system was used for assessing the fitness of a patient 
prior to surgery. It ranged from a healthy patient with no systemic illness 
to a moribund state. It has been used in assessing comorbidity and is 
simple to use (Riechelmann et al., 2006). Limitations of the system include 
the transferability of a fitness for surgery scale to patients with lung 
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cancer, for the majority of whom surgery is not a therapeutic option. In 
addition there is a well documented inter-user variability and lack of clear 
guidance for how to score a variety of significant diseases (Haynes et al., 
1995) 
 
None of the available tools for assessing comorbidity have been designed 
with lung cancer as the main focus of data collection. Thus researchers 
are faced with difficulty in identifying which system to use in studies of 
comorbidity in lung cancer patients. 
 
2.3 Tools available to assess comorbidity specifically in lung cancer 
 
Currently, there is only one tool that has been validated in lung cancer. 
Colinet et al in 2005 studied the outcome in Non Small Cell Lung Cancer 
(NSCLC) within 5 French territorial divisions. A prospective study of 735 
consecutive patients between 1998–2003 evaluated treatment and 
prognosis.  They used a Simplified Comorbidity Score (SCS) and also 
assessed Performance Status (PS), weight loss, age and the Charlson 
Comorbidity Index (CCI). It was shown that worsening stage, PS and SCS 
(>9) or CCI (>5) were independent adverse prognostic factors in terms of 
survival. Hazard ratio was 1.36 [1.09–1.69] Criticisms of this tool include 
the fact that SCS does not give any grading of disease severity or allow for 
more than one disease within a group e.g. a patient with both a stroke and 
ischaemic heart disease. In addition the reason for the extremely high 
weighting given to diabetes mellitus and smoking in comparison to 
respiratory and cardiac comorbidity is not made clear by the authors. Our 
own (published in abstract only) work (Milroy et al., 2005; Milroy et al., 
2009) suggests that diabetes mellitus has minimal if any impact on the 
treatment of patients with lung cancer. However it is certainly a 
straightforward tool to use in clinical practice. 
 
 
 
	   40	  
2.4 Association between comorbidity and cancer survival 
 
The possible prognostic impact of comorbidity on cancer patient survival 
was previously studied by Read et al (Read et al., 2004). A prospective 
cohort study was undertaken using the local cancer registry and 11,558 
patients with a variety of cancers were identified. The severity of patient 
comorbidity was assessed using the Adult Co-morbidity Evaluation 27 
(Piccirillo. 1995). The 1 year survival was determined for each tumour site 
and stage combination. The results suggested that the impact of 
comorbidity was greatest among tumour types with the longest survival 
i.e. those with the most indolent course such as prostate cancer. This 
suggests that comorbidity should have less effect on treatment or survival 
in aggressive tumour types such as lung cancer. 
 
These findings are not to be questioned.  However this study was primarily 
evaluating inter-tumour type variations in survival. It did not compare 
survival within a heterogeneous group of lung cancer patients or attempt 
to identify causes for such variations.  
 
 
2.5 Association between comorbidity and lung cancer outcome 
 
In most cancer trials significant comorbidity is an exclusion criteria. 
Consequently trial data may be of limited relevance to every day clinical 
practice with patients, the majority of whom will have co-existing 
comorbidities, and would therefore have been excluded from the original 
trial upon which their proposed treatment may be based.  It is therefore 
essential to assess what, if any, relationship has been shown in the 
literature between comorbidity and outcome in lung cancer. Although 
sparse, a number of studies have suggested that comorbidity has a 
significant impact on both treatment and outcome in lung cancer. 
However these studies suffer from a number of limitations. 
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Potosky et al (Potosky et al., 2004) retrospectively evaluated 898 patients 
with Non-small Cell Lung Cancer (NSCLC) and variations in initial 
treatment. Using National Guidelines, recommended treatment strategies 
were determined. Information that might influence treatment was 
recorded. This included stage, age, and comorbidity (using the Charlson 
Comorbidity Index, smoking status and race. Overall only 52% of patients 
received recommended therapy. The use of recommended therapy 
declined with increasing age and tumour stage. There was also a reported 
detrimental association with increasing comorbidity. This would be in 
keeping with most general clinical experience although there has been 
criticism of the effect of co-morbidity upon treatment in at least one 
previous article (Janssen-Heijnen et al., 2004) which is described in the 
next section 
 
A previous study by Earle (Earle et al., 2000) evaluated chemotherapy 
utilisation for patients with stage IV NSCLC and demonstrated that younger 
patients and those with fewer comorbid conditions were more likely to 
receive chemotherapy. It was however a retrospective analysis. 
 
An analysis from Wisconsin, USA(Firat et al., 2002) showed that KPS and 
comorbidity (recorded yes/no) were important independent prognostic 
factors in Stage III NSCLC. The limitations of this study include the focus 
on one tumour stage, and the fact it was a retrospective analysis of four 
Radiation Therapy Oncology Group studies evaluating survival benefit with 
radiotherapy alone. It was not a prospective study and did not have 
comorbidity as a primary explanatory variable. 
 
Kates et al (2009) recently retrospectively reviewed their localised lung 
cancer patients (Stage I – IIIA) and attempted to predict those likely to 
suffer from perioperative mortality (POM). It was shown that risk of death 
was significantly increased with a Charlson Comorbidity Index Score of 
greater than 4. Acute Myocardial Infarction, perhaps not surprisingly, had 
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the strongest association. Other factors associated with increased POM 
included increasing age, male gender and extent of surgical resection. 
 
Thus there is an indication that comorbidity has a relevance to 
management decisions in lung cancer. However, these studies did not 
explore actual survival. 
 
 
 
2.6 Studies comparing comorbidity and survival in lung cancer 
 
A number of articles have attempted to clarify the impact of comorbidity 
on lung cancer survival. 
 
Tammemagi et al (2004) evaluated comorbidity and its association with 
smoking on lung cancer survival. One thousand one hundred and fifty five 
patients who were diagnosed with lung cancer between 1995 and 1998 
were identified and retrospective analysis was performed to assess the 
impact of smoking on survival. It was shown that current smokers’ hazard 
ratio for death was significantly increased compared to former/never 
smokers 1.37 (95% confidence interval 1.18-1.59; p<0.001). Sixteen 
significant comorbid conditions were recorded. Sub-group analysis of these 
was also performed. A number of these comorbid factors were found to be 
independent predictors of survival. However, it should be noted that this 
was not the primary aim of the study and it was retrospective. 
 
Janssen-Heijnen (Janssen-Heijnen et al., 2004) evaluated 4072 patients 
with NSCLC. The authors assessed a number of comorbidities using a very 
slightly adapted version of the Charlson Comorbidity Index along with age, 
tumour size and proposed treatment. This study was, however, 
retrospective and used a comorbidity index not validated in lung cancer. 
Univariate and multivariate analyses of survival were performed. One year 
survival decreased significantly with age (p<0.0001). Comorbidity was not 
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found to have any influence on survival; however comorbidity was 
recorded as actual number of diseases ranging from 0 to 2 with no attempt 
to quantify the severity of comorbidity.  
 
Birim et al (2005) reported the assessment of the impact of the Charlson 
Comorbidity Index (CCI) in patients with NSCLC treated with surgery and 
the impact of the CCI score on survival. With multivariate analysis it was 
shown that for a CCI score >3 the relative risk of death was 2.2 (95% CI 
1.5–3.1). However with a score of 1 or 2 the relative risk was 1.4 (95% 
CI1.0–1.8). This showed a significant negative correlation on overall 
survival, which is decreased with increasing CCI score, suggesting that 
worsening comorbidity did impact negatively on survival. Limitations of 
this study include the absence of a grade of disease severity and that the 
study period was rather prolonged. In addition the authors failed to assess 
early stage NSCLC patients deemed ineligible for surgery. 
 
Imperatori et al (2006) compared management and survival between 
Teeside (UK), which has very similar population demographics to Scotland, 
and Varese (Italy), which does not. Data were recorded prospectively. The 
study revealed that Teeside had statistically significantly more advanced 
disease, higher comorbidity at presentation and lower survival rates. 
Comorbidity was recorded simply as yes/no with no grading of severity. It 
did not show any impact on survival. Only surgical resection was shown in 
multivariate analysis to be a positive predictor of survival (HR 0.46; p= 
0.0016). The overall 2 year survival was 14% for Italy and 7% in Teeside (p< 
0.001). Interestingly survival was relatively low by any European standard 
in both Italy and England (Janssen-Heijnen et al., 1998) 
 
Asmis et al (2008) retrospectively assessed two other studies recently 
undertaken by the National Cancer Institute of Canada Clinical Trials 
Group. The paper by Asmis evaluated age, comorbidity and performance 
status as factors that might influence survival. The Charlson Comorbidity 
Index assessed comorbidity.A CCI score of 1 was associated with a poorer 
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overall survival compared to 0 (hazard ratio [HR 1.28; 95% CI 1.09-1.5; p= 
0.003). For a CCI >1 there was no additional effect seen. It must be noted 
that very few patients fell into the category of having CCI>1. Age was not 
shown to be an independent factor. As with most clinical trials these did 
not include unfit, poor performance status patients.  It must also be noted 
that the comorbidity data was collected retrospectively. This was a highly 
selected group of patients as only relatively fit, good performance status 
patients were eligible for trial enrolment. In addition previous studies 
have shown that higher social class patients are more likely to be offered 
trial enrolment (Mosenifar et al., 2007). It would, therefore, be 
inappropriate to make significant judgement about the impact of 
comorbidity based on this report alone. 
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2.7 Conclusion 
 
Lung cancer is a major cause of death and imposes a significant burden on 
health care systems throughout the developed world. Nearly 40,000 new 
cases were reported in 2008 in the UK (Ferlay et al., 2007). Furthermore, 
with the increase in smoking and increasing life expectancy in the 
developing world, lung cancer is likely to place an increasing burden on 
the health services of developing countries in the future. 
 
Factors such as age, performance status and social class are often seen as 
correlates for comorbidity. Therefore any attempts to both evaluate and 
quantify comorbidity will require taking into account these additional 
factors if we are to determine the underlying reasons for the poor 
prognosis in lung cancer and regional variations in survival. 
 
At present there is little published work in the field of comorbidity in lung 
cancer. None of the previous comorbidity tools were designed specifically 
for lung cancer, with the exception of the study by Colinet et al and most 
have been adapted from other uses. No published studies have definitively 
demonstrated and prospectively quantified the impact of comorbidity on 
treatment decision making and on overall survival. There is a clear need 
for further prospective studies to attempt to clarify further the impact of 
comorbidity in lung cancer patients. Finally a specific tool designed for, 
and validated in the lung cancer setting will be essential if we are to truly 
understand the multi-factorial nature of variations in treatment and 
survival within the lung cancer population.  
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CHAPTER 3: METHODS 
 
3.1 Introduction 
 
Four Scottish centres were included in the study. These non-tertiary 
centres routinely investigate, diagnose and treat patients with lung cancer 
who live in demographically contrasting areas of Scotland (Grose et al., 
2011). Healthcare coverage in Scotland is universal, free at the point of 
need and highly centralised. National guidelines state that all newly 
diagnosed lung cancer patients should be referred to a Respiratory 
Physician and discussed at a Multi-Disciplinary Meeting (MDT) (SIGN, 2005). 
All four centres involved in this study adhere to this with a greater than 
90% success (Managed Clinical Network audit report, WOSCAN, 2011) with 
the majority of referrals being made by General Practitioners or via 
unscheduled acute hospital admission with a minority from radiologists 
and surgeons. This ensured that patients included in the study would be 
representative of the underlying lung cancer population. Consecutive 
patients diagnosed with lung cancer were included in the study but 
because of local factors the centres did not recruit for the same periods of 
time. The study periods for each centre were Aberdeen, October 2005 to 
February 2007; Stobhill, December 2005 to April 2008; Inverclyde, October 
2005 to December 2007 and Dunfermline, June 2007 to April 2008. All 
newly diagnosed lung cancer patients, whose care was discussed at the 
Multi-Disciplinary Team (MDT) meeting, were included in the study.  
 
3.2 Data Collection 
 
At the time of the patient’s case being discussed at the MDT, anoymised 
details were entered into a specifically designed Microsoft Access database 
(The proforma is presented in Appendix 1). Patient demographics and 
baseline characteristics (age, sex, postcode and smoking history), PS, 
weight loss, laboratory parameters (C-reactive protein, albumin, 
creatinine and ventilatory function, wherever possible this was based on 
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full lung function testing, if unavailable spirometry was used), 
comorbidites (including severity), tumour stage (Detterbeck et al., 2009) 
and histology and primary treatment proposed by the MDT were all 
recorded.  
 
Those team members involved in the decision-making processes were also 
recorded. The doctor delivering the treatment (e.g. thoracic surgeon or 
clinical oncologist) would have the final say on treatment, thus limiting 
any potential discrepancy between recommended and delivered 
treatment. If the primary treatment decision differed from that 
recommended by the 2005 Scottish Intercollegiate Guidelines Network 
(SIGN) guidelines on the management of patients with lung cancer (SIGN, 
2005) the reason(s) were recorded (for example age, poor performance 
status, comorbidity, patient choice). If a histological diagnosis was not 
achieved this was recorded with reason(s) (for example failed procedure, 
age, poor performance status, comorbidity, non-diagnostic investigations, 
patient choice). All investigations attempted, clinical/radiological stage 
and primary treatment plan were itemised.  
 
All four MDTs had input from both a clinical oncologist and thoracic 
surgeon. Assesment of patient including PS was made by a Respiratory 
Physician at point of diagnosis prior to MDT treatment plan. All data was 
recorded in real time at the MDT and at first clinic attendance by one of 
the clinical staff (either a respiratory physician or clinical nurse 
specialist), taking on average 2 -3 minutes to enter the data. 
 
 
3.3 Socioeconomic Status 
 
Information on patients’ individual educational or occupational social class 
was not available, and we therefore used their postcode of residence as a 
proxy indicator of their socioeconomic status. Using the 2006 Scottish 
	   48	  
Index of Multiple Deprivation (SIMD) ranking (Office of Chief Statistician, 
2006) (see box 1) the postcode enabled us to group patients into one of 5 
quintiles.  
 
Box 1 – Scottish Index of Multiple Deprivation (SIMD) 
 
The 2006 SIMD is a validated area-based index that uses 37 indicators in 
seven domains to rank 6505 small geographic areas in Scotland (data 
zones) from 1 (most deprived) to 6505 (least deprived). These can be 
subsequently grouped into quintiles. These split up the datazones into 5 
groups, each containing 20% of Scotland’s datazones. The first quintile 
contains the 20% most deprived datazones with the fifth representing the 
20% least deprived. 
 
 
3.4 Comorbidities and Severity Scores 
 
Comorbidities present in each patient, with severity of each graded on a 
four point scale (0, 1, 2, 3) using a novel severity scales (Table 3.1) were 
recorded, in real time, by a clinician at time of review. The severity index 
was developed using, where possible, previously validated scoring systems 
(GOLD Guidelines, 2004; Little et al., 1994; Lyden et al., 2001; Morris, 
1993;). This included use of the British Thoracic Society guidelines for 
Chronic Obstructive Pulmonary Disease, the Canadian Cardiovascular 
Society Classification for Ischaemic Heart Disease, the New York Heart 
Association classification for Heart Failure, the National Institutes of 
Health Stroke Scale for Cerebrovascular disease and the Clinical Dementia 
Rating. For comorbidities without a validated severity scale we used a 
scale based on local discussion with eminent regional experts in that 
particular field. 
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Table 3.1 Comorbidities and severity scales assessed for each 
subject in the study 
Comorbidity Severity scale Severity Score 
0 1 2 3 
COPD BTS/GOLD 
guidelines 
No disease FEV1 > 60% FEV1 40-60% FEV1 < 40% 
 
Ischaemic heart 
disease 
Canadian CV 
Society 
Classification 
No disease 
 
Angina with 
strenuous/ 
prolonged 
exertion 
Angina after 
walking 200 
hundred yards 
flat/flight stairs 
Inability to 
carry out 
any level of 
exertion/an
gina at rest 
Heart failure NYHA 
classification 
No disease 
 
Slight limitation 
of physical 
activity due to 
dyspnoea 
Comfortable at 
rest, less than 
ordinary activity 
causes dyspnoea 
Dyspnoea at 
rest 
Cerebrovascular 
disease 
National 
Institutes of 
Health Stroke 
Scale 
No detectable 
weakness/ 
sensory (incl 
visual/speech) 
impairment 
 
Mild weakness/ 
deficit 
 
Moderate 
weakness/ deficit 
 
Severe 
weakness/ 
deficit 
 
Dementia Clinical Dementia 
Rating 
No disease Mild, able to 
carry out 
normal activity 
Moderate, 
requires 
assistance in 
activities 
Severe, 
unable to 
manage any 
activity. 
Full time 
care 
Diabetes 
mellitus 
 No disease HbA1C < 7 
 
HbA1C 7.1 - 10 
 
HbA1C> 10 
 
Renal function  eGFR> 
90ml/min 
 
eGFR 60-89 
ml/min 
 
eGFR 30-59 
ml/min 
 
eGFR 
<30ml/min 
or dialysis 
 
Previous 
malignancy 
 
 No disease or 
Basal Cell 
Carcinoma 
 
Previous cancer, 
no evidence 
active disease 
Active, unlikely 
to cause death 
Active, 
likely to 
cause death 
before lung 
cancer 
Peripheral 
Vascular Disease 
 
 None 
 
Claudication at 
> 200 yards 
 
Claudication at < 
200 yards 
 
Rest pain 
Alcohol  <25 Units/week 25-50 
units/week 
>50 units/week Establishd 
alcohol 
related 
illness or 
end organ 
failure 
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Figure 3.1: Flowchart of patient numbers in study 
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3.5 Survival data 
 
Information on date of death was obtained via survival analysis undertaken 
by the Information Service Division (ISD) of NHS Scotland. Death records 
were complete until 1 June 2011, which served as the censor date for 
those alive. 
 
 
3.6 Ethics 
The audit was discussed with the local ethics department and as it was 
health service clinical practice audit formal ethical approval was deemed 
not to be necessary. 
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CHAPTER 4: VARIATION IN COMORBIDITY AND 
CLINICAL MANAGEMENT IN NEWLY DIAGNOSED LUNG 
CANCER PATIENTS IN FOUR SCOTTISH CENTRES 
 
4.1 Introduction 
 
Lung cancer is the commonest cause of cancer death for both men and 
women in Scotland (Office for National Statistics, 2006; ISD, 2009). 
Although survival has improved over the past decade, it remains 
significantly poorer in Scotland than in comparable Western European 
countries or the USA, with 5-year relative survivals of 8.0%, 10.2% and 
16.3%, respectively.  Variations in treatment may explain some of the 
observed differences in lung cancer survival between countries (Berrino et 
al., 2007; Horner et al., 2009). Surgical resection rates in the United 
Kingdom (≤10%) are consistently reported to be lower than those in Europe 
and North America, which are in excess of 20% (Fry et al., 1999; Laroche 
et al., 1998; Cartman et al., 2002; Damhuis et al., 1996). There also 
appear to be variations in treatment rates between healthcare sites within 
Scotlandthat might give insights into inequalities in survival (Gregor et al., 
2001; Janssen-Heijnen et al., 1998). However, variations in treatment do 
not wholly explain survival differences between countries and other 
patient characteristics, including comorbidities, may need to be 
considered. A number of studies have indicated that comorbid factors 
influence both choice of therapy, as well as directly affecting survival 
(Potosky et al., 2004; Earle et al., 2000; Extermann, 2000; Charlson et al., 
1987; Tammemagi et al., 2004; Janssen-Heijnen et al., 2004; Colinet et 
al., 2005; Birim et al., 2005; Imperatori et al., 2006; Asmis et al., 2008; 
Erridge et al., 2009). However, the investigation of comorbidities has not 
been the primary aim of any of these studies and the quantification of 
comorbidities has lacked precision, having been either dichotomised into 
yes/no categories or expressed as the crude number of co-existent 
diseases.  
	   53	  
To date, no study of lung cancer has attempted to investigate specifically 
the association between inter-hospital variations in investigation and 
treatment, and the type and severity of comorbidities. In a pilot study we 
screened 50 newly diagnosed lung cancer patients presenting sequentially 
to the Lung Cancer Service at Stobhill General Hospital, Glasgow (Milroy et 
al., 2005). This pilot study suggested a relationship between increasing 
comorbidity, worsening performance status and clinicians’ inability to 
offer either potentially curative treatment or optimal palliative 
treatment. Building on the results of the pilot study we have conducted a 
study in four Scottish centres to identify prospectively any difference in 
the investigation and treatment of patients diagnosed with lung cancer. In 
addition we have quantified the number and severity of co-morbid 
conditions to investigate how different comorbidity contributes to 
observed variation in clinical management.  
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4.2 Methods  
 
Previously described in chapter 3 
 
 
 
Statistical methods 
 
Statistical analyses were performed using SPSS v17.0 (SPSS Inc., Chicago, 
USA). The primary outcome variable of interest was the primary treatment 
option decided by the MDT. Univariable analyses using χ2, t-tests and 
ANOVA were used to explore the associations between treatment options 
and potential explanatory variables such as tumour stage, performance 
status, age, sex, SIMD, co-morbidities (expressed as ordinal scores) and 
FEV1. Potential explanatory variables with p<0.1 on univariable testing 
were included in a multiple logistic regression model to identify 
associations between treatment options and co-morbidities after 
adjustment for other potentially influential factors. 
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4.3 Results 
 
Between Centre Differences 
 
In total 882 patients were included in the study, comprising 297 from 
Aberdeen, 136 from Dunfermline, 285 from Glasgow and 164 from 
Inverclyde.  The mean age of participants was 70.4 years and 55.2% were 
male.  There were marked differences between centres in the socio-
economic status profiles of the patients with the majority of patients at 
Glasgow, but none in Dunfermline, living in the most deprived 
circumstances, and less marked, but significant differences in age, sex and 
smoking history profiles (Table 4.1). There were clear differences in the 
comorbidity severity score profiles between centres for COPD (Fig 4.1a), 
ischaemic heart disease (Fig 4.1b), congestive cardiac failure (χ2,p<0.001), 
dementia (χ2,p=0.008), diabetes mellitus (χ2,p=0.001), renal function 
(χ2,p<0.001), weight loss (χ2,p<0.001), alcohol intake (χ2,p<0.001), but 
there were no significant between centre differences in the severity score 
profiles for cerebrovascular disease, previous malignancies or peripheral 
vascular disease. Performance status also varied between centres (Table 
4.1), as did rate of deterioration in performance status. There was 
suggestion of between centre differences in the proportion of patients 
diagnosed with small cell cancer, with no differences in the stage profile 
(Table 4.1). 
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Table 4.1  Between centre differences in patient profile 
 
 All centres 
n=882 
Aberdeen 
n=297 
Dunfermline 
n=136 
Glasgow 
n=297 
Inverclyde 
n=164 
p value* 
(between 
centres) 
Age Mean (95% CI) 70 
(70-71) 
69 
(68-70) 
71 
(69-73) 
71 
(69-72) 
73 
(71-74) 
0.001 
% male 55% 60% 58% 49% 54% 0.049 
Ever smoked 94% 94% 97% 93% 94% 0.35 
Mean pack year 
consumption (95% 
CI) 
44 
(42-46) 
46 
(42-49) 
38 
(35-41) 
44 
(41-47) 
44 
(39-49) 
0.023 
Socio-economic 
status % in most 
deprived quintile of 
SIMD 
30% 5% 0 64% 42% <0.001 
Socio-economic 
status % in most 
affluent quintile of 
SIMD 
7% 19% 0 0 4% <0.001 
% Performance 
status 0/1 6 months 
prior to 
presentation 
79% 81% 82% 76% 78% 0.47 
% Performance 
status 0/1 at 
presentation 
47% 58% 53% 43% 28% <0.001 
% Performance 
status fell from 0/1 
to 2/3/4 in 6 
months prior to 
presentation 
41% 28% 36% 44% 65% <0.001 
FEV1 % predicted 
Mean (95% CI) 
64% 
(62-65) 
62% 
(60-65) 
65% 
(61-69) 
67% 
(64-69) 
59% 
(55-63) 
0.018 
Serum creatinine 
Mean (95% CI) 
nmol/l 
93 
(90-96) 
93 
(89-97) 
100 
(92-107) 
87 
(83-91) 
97 
(89-105) 
0.008 
Serum albumin 
Mean (95% CI) g/l 
37 
(36-37) 
40 
(39-41) 
36 
(35-37) 
33 
(32-34) 
37 
(36-37) 
<0.001 
CRP mg/l 
Mean (95% CI) 
48 
(44-53) 
46 
(39-53) 
62 
(39-74) 
45 
(38-52) 
56 
(45-67) 
0.21 
% Non Small Cell 62% 58% 60% 59% 76% 0.001 
% Small Cell 13% 15% 7% 16% 12% 0.077 
% Small Cell Limited 
Disease 
29% 
(33/115) 
22% 
(10/45) 
20%  
(2/10) 
34%  
(14/41) 
37% 
 (7/19) 
0.47 
% Non Small Cell 
Stage I or II 
21% 
(109/531) 
27% 
(47/173) 
22% (18/81) 18%  
(27/153) 
14% 
(17/124) 
0.028 
% No histology Stage 
I or II 
18% 
(31/173) 
12%  
(6/50) 
20%  
(8/41) 
21%  
(17/81) 
0%  
(0/1) 
0.57 
 
*ANOVA, χ2 tests of statistical significance 
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Figure 4.1 Bar chart illustrating between centre differences in 
severity scores for (a) chronic obstructive pulmonary disease (COPD) 
and (b) ischaemic heart disease (IHD). Between centre p values 0.017 
for COPD and <0.001 for IHD, 
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There were marked differences between centres in the investigations 
performed to stage and characterise lung cancer. In Dunfermline, for local 
reasons, measurement of CRP was about a third that of other sites 
(χ2,p<0.001) and histological diagnosis was lower (χ2,p<0.001) (Table 4.1). 
The majority of the patients had NSCLC (62.0%), 13.4% had SCLC and the 
remainder of patients had no pathological confirmation. There was 
variation in non-small cell stage at presentation between centres with the 
incidence of stage I or II disease ranging from 13.7% of patients at 
Inverclyde to 27.2% of patients in Aberdeen (χ2,p= 0.028) (Table 4.1). This 
is clinically important, as stage at presentation is one of the most 
important factors in determining treatment and survival (Mountain, 1986). 
The proportion of patients presenting with limited stage SCLC varied 
between centres from 36.8% at Inverclyde to 20.0% in Dunfermline, but 
probably because of low numbers this difference was not statistically 
significant (Table 4.1).   
 
Between centre differences were observed in the rates of radical 
radiotherapy, the proportion of patients with locally advanced/metastatic 
NSCLC having chemotherapy and the proportion of patients for who best 
supportive care with no surgical/oncological intervention was 
recommended. The differences between sites in proportions of patients 
referred for surgical resection were small and not statistically significant 
(Table 4.2). 
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Table 4.2  Between centre differences in investigation and 
treatment 
 
 All 
centres 
n=882 
Aberdeen 
n=297 
Dunfer
mline 
n=136 
Glasgow 
n=297 
Inverclyd
e 
n=164 
p value* 
(betwee
n 
centres) 
Measurement of CRP 86.3% 96.6% 37.5% 94.7% 93.3% <0.001 
Obtained histological 
diagnosis 
75.5% 73.4% 66.9% 74.9% 87.2% <0.001 
Surgical resection 6.3% 7.4% 6.6% 5.6% 5.5% 0.79 
Radical Radiotherapy 4.0% 4.0% 8.8% 3.1% 0.6% 0.004 
Chemotherapy NSCLC 
stage IIIb/IV 
4.0% 9.8% 0% 2.8% 0% <0.001 
No 
surgery/chemo/radiot
herapy 
20.6% 10.8% 36.8% 22.5% 22.0% <0.001 
*χ2 or Fishers exact tests of statistical significance 
 
 
 
Associations with Performance Status 
 
Of the 882 patients 46.8% (413) had a performance status of 0 or 1 at time 
of diagnosis. Univariable analysis demonstrated that a performance status 
of 0/1 was associated with centre (Aberdeen 58.2%, Fife 52.9%, Stobhill 
42.8%, Inverclyde 28.0%, Table 4.3 model 1, χ2,p<0.001), younger age 
(67.6 years 95% CI 66.5-68.7 vs. 72.4 (71.2-73.5), t test, p<0.001), those in 
more affluent areas as defined by SIMD, (highest quintile of affluence 
62.9% PS 0/1 vs. lowest quintile 40.4%, χ2,p<0.001) and those with a 
confirmed pathological (i.e. either cytological or histological) diagnosis 
(SCLC 48.7%, NSCLC 53.3%, no histology 32.4%, χ2,p<0.001). Univariable 
analysis demonstrated that performance status was adversely associated 
with increasing severity of the comorbidities: COPD, IHD, CCF, 
cerebrovascular disease, dementia, renal impairment, weight loss, 
peripheral vascular disease and alcohol history. There were no associations 
with sex, or severity of diabetes mellitus. Multivariable modeling 
demonstrated that a performance status of 0/1 was less likely with 
increasing age, some centres (Glasgow and Inverclyde), and increasing 
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severity of the comorbidities COPD, CCF, cerebrovascular disease and 
dementia (Table 4.3). Reduced performance status at presentation (PS 
2/3/4) was associated with NSCLC stage IV, extensive SCLC and failure to 
achieving positive tumour histology. The predictive power of the final 
logistic regression model to identify correctly individuals with a 
performance status of 0/1 was assessed using receiver operating 
characteristic (ROC) curve analysis. The area under the ROC curve for the 
final logistic model was 0.79 indicating fair to good discrimination 
(although as this was tested on the same cohort of patients from which it 
was derived this may appear artificially good). 
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Table 4.3  Results of univariable analysis relating performance status 
0/1 to centre (model 1). Model 2 is the results of multiple logistic 
regression modeling relating performance status 0/1 to centre, age, 
comorbidity scores (for COPD, CCF, cerebrovascular disease, dementia, 
weight loss), and tumour stage, and histology, 
 
 Model 1 Model 2 
Odds ratio (95% CI) p value Odds ratio (95% CI) p value 
Aberdeen      (n=173)  1  1  
Dunfermline  (n=72) 0.87 (0.54-1.21) 0.30 1.50 (0.90-2.49) 0.12 
Glasgow        (n=122) 0.54 (0.39-0.75) <0.001 0.47 (0.32-0.71) <0.001 
Inverclyde     (n=46)  0.28 (0.19-0.42) <0.001 0.29 (0.18-0.46) <0.001 
     
Age (years)     
<60           (n=80)   1 <0.001* 
    60-70        (n=142)   0.85 (0.51-1.41)  
    70-80        (n=149)   0.58 (0.35-0.95)  
>80           (n=42)   0.25 (0.14-0.45)  
     
COPD (FEV1 % predicted)     
>80%        (n=252)   1 <0.001* 
    60-80%     (n=80)   0.93 (0.59-1.48)  
    40-60%     (n=64)   0.54 (0.35-0.83)  
<40%         (n=42)   0.22 (0.10-0.48)  
     
CCF (severity score)     
    0             (n=369)   1 0.002* 
    1             (n=35)   0.67 (0.38-1.17)  
    2             (n=6)   0.21 (0.08-0.59)  
    3             (n=1)   0.33 (0.03-3.63)  
     
Cerebrovascular disease (severity 
score) 
    
    0           (n=800)   1 <0.001* 
    1           (n=52)   0.58 (0.29-1.16)  
    2           (n=18)   0.12 (0.02-0.62)  
    3           (n=8)   0.00 (0.00-      )+  
     
Dementia (severity score)     
    0           (n=827)   1 0.002* 
    1           (n=24)   0.59 (0.19-1.86)  
    2           (n=14)   0.34 (0.08-1.50)  
    3           (n=1)   0.00 (0.00-      )+  
     
Weight loss      
    None     (n=416)   1 <0.001* 
<5%       (n=131)   0.47 (0.28-0.78)  
    5-10%    (n=74)   0.49 (0.27-0.91)  
>10%     (n=258)   0.20 (0.14-0.30)  
     
NSCLC stage I/II   (n=136)   1  
NSCLC stage III    (n=233)   0.67 (0.40-1.13) 0.13 
NSCLC stage IV    (n=311)   0.37 (0.22-0.62) <0.001 
SCLC limited       (n=33)   0.52 (0.22-1.28) 0.15 
SCLC extensive    (n=82)   0.47 (0.25-0.91) 0.026 
No histology        (n=26)   0.42 (0.20-0.89) 0.023 
*: p value for trend across categories 
+: upper 95 CI not computable 
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Predictors of decline in performance status. 
 
Of the 694 patients with a retrospectively estimated performance status of 
0 or 1 six months prior to diagnosis, 40.9% had declined by the time of 
presentation. Univariable analysis demonstrated that a decline in 
performance status from 0/1 to 2/3/4 in the 6 months prior to 
presentation was associated with centre (Aberdeen 28.2%, Dunfermline 
35.5%, Glasgow 43.8%, Inverclyde 65.1%, χ2,p<0.001, Table 4.4 model 1), 
increasing age, increasing deprivation (highest quintile of affluence 18.8%, 
lowest quintile of affluence 46.8%), COPD, IHD, CCF, cerebrovascular 
disease, dementia, tumour histology and stage. Multivariable modeling 
(Table 4.4 model 2) demonstrated that a decline in performance status 
from 0/1 to 2/3/4 in the 6 months prior to presentation was associated 
with centre (more likely in Inverclyde), increasing age, decreasing 
affluence, COPD, CCF, cerebrovascular disease, tumour stage and tumour 
histology. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   63	  
Table 4.4:  Results of univariable analysis relating decline in 
performance status from 0/1 to 2/3/4 in the 6 months prior to 
presentation to centre (model 1). Model 2 is the results of multiple 
logistic regression modeling relating decline in performance status to 
centre, age, SIMD, and comorbidity scores (for COPD, CCF, 
cerebrovascular disease), and tumour stage and histology.  
 
 Model 1 Model 2 
 Odds ratio (95% 
CI) 
p value Odds ratio (95% 
CI) 
p value 
Aberdeen       (n=68) 1  1  
Dunfermline   (n=39) 1.40 (0.86-2.26) 0.17 1.07(0.62-1.83) 0.82 
Glasgow         (n=95) 1.98 (1.34-2.92) 0.001 1.48 (0.87-2.52) 0.15 
Inverclyde      (n=82) 4.74 (2.99-7.52) <0.001 3.87 (2.27-6.60) <0.001 
     
Age (years)     
<60            (n=36)   1 <0.001* 
    60-70         (n=77)   1.15 (0.68-1.97)  
    70-80         (n=102)   1.47 (0.87-2.49)  
>80            (n=69)   3.33 (1.77-6.28)  
     
Quintile affluence (SIMD)     
     Q1: Least affluent(n=94)   1 0.047* 
     Q2(n=49)   1.39 (0.76-2.55)  
     Q3                          (n=90)   1.06 (0.65-1.73)  
     Q4                          (n=42)   0.77 (0.41-1.47)  
     Q5: most affluent    (n=9)   0.34 (0.13-0.88)  
 
 
 
 
    
COPD (FEV1 % predicted)     
>80%      (n=154)   1 <0.001* 
    60-80%   (n=44)   1.03 (0.62-1.70)  
    40-60%   (n=63)   1.71 (1.07-2.73)  
<40%       (n=22)   4.12 (1.80-9.45)  
     
CCF (severity score)     
    0           (n=243)   1 0.008* 
    1           (n=31)   1.97 (1.08-3.59)  
    2           (n=8)   3.46 (1.01-11.9)  
    3           (n=1)   2.76 (0.16-46.8)  
     
Cerebrovascular disease (severity 
score) 
    
    0          (n=257)   1 0.007* 
    1          (n=20)   1.84 (0.85-3.99)  
    2          (n=6)   7.70 (1.27-46.9)  
    3           (n=0)   ++  
     
NSCLC stage I/II    (n=21)   1  
NSCLC stage III      (n=72)   2.63 (1.43-4.84) 0.002 
NSCLC stage IV      (n=119)   5.60 (3.09-10.1) <0.001 
SCLC limited         (n=11)   3.22 (1.22-8.47) 0.018 
SCLC extensive     (n=28)   3.98 (1.90-8.32) <0.001 
No histology         (n=23)   4.37 (1.94-9.87) <0.001 
     
 
*: p value for trend across categories 
++: OR not computable (too few subjects in category) 
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Associations with surgical resection for NSCLC 
 
The surgical resection rates for confirmed NSCLC were 12.7% (Aberdeen), 
11.1% (Dunfermline), 10.5% (Glasgow) and 7.3% (Inverclyde) but the 
differences were not statistically significant. Given the differences in the 
patient profiles between centres, multivariable modeling was performed 
and the results are outlined in Table 4.5 as model 1. After adjustment, 
there were the expected associations between surgical resection, 
performance status and tumour stage. Female sex and increasing age were 
associated with a reduced likelihood of surgical resection. The only co-
morbidity significantly associated with the reduced chance of surgical 
resection was COPD. The multivariable analysis indicated that after 
adjustment for performance status, tumour stage, age, sex and COPD, 
patients in Inverclyde were more than five times likely to be operated on 
for NSCLC than patients from Aberdeen. It was also noted however that 
the number of patients with Stage 1 and II NSCLC who declined surgical 
treatment differed between centres: 25% (Aberdeen 3/12), 50% 
(Dunfermline 5/10), 0% Glasgow (0/7) and Inverclyde (0/8) (χ2,p=0.009) 
and that women were more likely to decline surgical treatment than men 
(21.7% vs. 11.5%) although this difference was not statistically significant. 
Patient refusal was not associated with socio-economic status. If the 
patients with Stage I or Stage II NSCLC who declined surgery had actually 
been operated on (Table 4.5 model 2) the sex and age associations with 
surgical resection were not significant and patients in Dunfermline were 
more likely to undergo surgical resection. 
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Table 4.5 Results of multiple logistic regression relating decision to 
treat non-small cell lung cancer by surgical resection to centre, sex, 
age, comorbidity, performance status, and tumour stage. Model 1: 
subjects who declined surgical intervention coded as no surgery, Model 
2: subjects who declined surgical intervention coded as surgical 
intervention. 
 
 
 Model 1 Model 2 
 Odds ratio (95% CI) p value Odds ratio (95% CI) p value 
Aberdeen       (n=22) 1  1  
Dunfermline   (n=9) 1.19 (0.28-5.00) 0.81 4.39(1.14-16.9) 0.032 
Glasgow         (n=16) 2.49 (0.83-7.46) 0.10 1.57(0.55-4.41) 0.40 
Inverclyde      (n=9) 5.84 (1.50-22.7) 0.011 2.77(0.77-10.0) 0.12 
     
Female sex     (n=22) 0.39 (0.16-0.96) 0.041 0.53(0.22-1.31) 0.21 
     
Age (years)     
<60           (n=9) 1 0.007* 1 0.051* 
    60-70        (n=25) 0.56 (0.13-2.47)  1.03(0.22-4.90)  
    70-80        (n=21) 0.37 (0.08-1.66)  0.60(0.13-2.82)  
>80           (n=1) 0.02(0.001-0.29)  0.10(0.01-0.79)  
     
COPD(FEV1% predicted)     
>80%         (n=32) 1 0.008* 1 0.012* 
    60-80%      (n=17) 0.36 (0.12-1.13)  0.37(0.13-1.08)  
    40-60%      (n=6) 0.26 (0.07-1.03)  0.29(0.08-0.99)  
<40%          (n=1) 0.10 (0.01-1.18)  0.14(0.02-1.21)  
 
 
 
 
    
Performance status      
    0              (n=21) 1 0.002* 1 0.018* 
    1              (n=27) 0.24 (0.07-0.88)  0.31(0.09-1.09)  
    2              (n=6) 0.08 (0.02-0.38)  0.18(0.04-0.76)  
    3              (n=2) 0.04 (0.01-0.53)  0.07(0.06-0.71)  
    4              (n=0) 0.00 (0.00-      )+  0.00(0.00-   )+  
     
Tumour stage      
    I               (n=38) 1 <0.001* 1 <0.001* 
    II              (n=14) 0.48 (0.18-1.30)  0.65(0.25-1.66)  
    IIIa           (n=4) 0.03 (0.01-0.14)  0.03(0.07-0.11)  
    IIIb           (n=0) 0.00 (0.00-      )+  0.00(0.00-    )+  
    IV             (n=0) 0.00 (0.00-      )+  0.00(0.00-    )+  
 
*: p value for trend across categories 
+: upper 95 CI not computable 
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Associations with radical radiotherapy for NSCLC 
 
There were clear between centre differences in the rates of radical 
radiotherapy (definition as per SIGN guidelines23) for NSCLC (Tables 4.2, 
4.6) that persisted after adjustment for factors found to be associated 
with radical radiotherapy for NSCLC on univariable analysis. Multivariable 
modeling also indicated that the decision to treat NSCLC with radical 
radiotherapy was more likely if the patient was a woman and in patients 
with COPD. There was a non-significant association between the decision 
to treat with radical radiotherapy and alcohol associated comorbidity.  
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Table 4.6 Results of univariable analysis relating decision to treat 
non-small cell lung cancer by high dose radical radiotherapy to centre 
(model 1). Model 2 outlines the results of multiple logistic regression 
modeling relating decision to treat by high dose radical radiotherapy to 
centre, sex, comorbidity (COPD, alcohol) and tumour stage. 
 
 Model 1 Model 2 
 Odds ratio (95% CI) p value Odds ratio (95% 
CI) 
p value 
Aberdeen       (n=31) 6.75 (0.84-54.0) 0.072 8.52 (0.98-74.3) 0.052 
Dunfermline   (n=19) 13.5 (1.65-110) 0.015 14.6 (1.54-137) 0.019 
Glasgow         (n=28) 8.60 (1.09-68.1) 0.042 9.84 (1.14-84.9) 0.038 
Inverclyde      (n=4) 1  1  
     
Female sex     (n=41)   2.56 (1.05-6.26) 0.040 
     
COPD (FEV1% predicted)     
>80%          (n=41)   1 0.023* 
    60-80%       (n=19)   3.79 (1.22-11.8)  
    40-60%       (n=19)   5.41 (1.62-18.0)  
<40%           (n=3)   3.68 (0.56-24.2)  
     
Alcohol (severity score)     
     0               (n=69)   1 0.063* 
     1               (n=7)   0.48 (0.09-2.70)  
     2               (n=3)   12.2 (0.84-178)  
     3               (n=2)   12.2 (0.89-168)  
     
NSCLC stage I/II (n=24)   1  
NSCLC stage III   (n=55)   0.24 (0.09-0.61) 0.003 
NSCLC stage IV   (n=0)   ++  
 
 
*: p value for trend across categories 
++: OR not computable (too few subjects in category) 
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Associations with optimal treatment of SCLC 
 
In total 13.4% of the patients were diagnosed with SCLC, with 28.7% staged 
as limited disease. Optimal treatment for limited stage SCLC was defined 
as chemotherapy with a platinum doublet along with consolidation 
radiotherapy to mediastinum (conventionally defined as at least 30Gy 
(SIGN, 2005) and brain, either sequentially or concurrently (SIGN, 2005). 
There was evidence of between centre differences in the incidence of 
SCLC, with Aberdeen highest and Dunfermline lowest (15.2 versus 7.4% of 
patients respectively) but probably because of small numbers these 
differences did not reach statistical significance (χ2,p=0.077) (Table 4.2). 
However, multivariable modeling suggested that after adjustment there 
were between centre differences in the decision to treat SCLC with 
optimal therapy, furthermore there were associations between optimal 
treatment and performance status, alcohol associated comorbidity and IHD 
comorbidity. (Table 4.7) 
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Table 4.7  Results of univariable analysis decision to treat small cell 
lung cancer with combination chemotherapy or concurrent 
chemoradiotherapy to centre (model 1). Model 2 outlines the results of 
multiple logistic regression modeling relating decision to treat small cell 
lung cancer with combination chemotherapy or concurrent 
chemoradiotherapy to centre to centre, comorbidity (alcohol, COPD), 
and performance status. 
 
 Model 1 Model 2 
 Odds ratio (95% CI) p value Odds ratio (95% CI) p value 
Aberdeen       (n=5) 1.07 (0.28-4.00) 0.92 0.24 (0.03-1.67) 0.15 
Dunfermline   (n=1) 0.27 (0.05-1.40) 0.12 0.05 (0.04-0.56)  0.016 
Glasgow         (n=12) 0.83 (0.22-3.07) 0.78 0.30 (0.05-1.95) 0.21 
Inverclyde      (n=5) 
 
1  1 
 
 
Ischaemic heart disease 
(severity score) 
    
     0             (n=14)   1 0.037* 
     1             (n=2)   0.48 (0.10-2.24)  
     2             (n=4)   0.06 (0.01-0.54)  
     3             (n=2)   1.14 (0.02-62.1)  
     
Alcohol (severity score)     
     0            (n=12)           1  
     1            (n=3)   0.37 (0.01-17.7) 0.010* 
     2            (n=2)   0.02 (0.01-0.39)  
     3            (n=1)   0.12 (0.01-2.09)  
 
 
 
 
    
COPD(FEV1% predicted)     
>80%        (n=14)   1 0.090* 
    60-80%     (n=5)   0.09 (0.01-1.15)  
    40-60%     (n=3)   0.39 (0.04-3.54)  
<40%         (n=1)   0.51 (0.01-2.18)  
     
Performance status      
    0             (n=3)   1 <0.001* 
    1             (n=11)   1.56 (0.11-23.2)  
    2             (n=9)   0.39 (0.03-4.64)  
    3             (n=0)   0.00 (0.00-)+  
    4             (n=0)   0.00(0.00-      )+  
 
 
*: p value for trend across categories 
+: upper 95 CI not computable 
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Associations with best supportive/palliative care 
 
For 182 patients (20.6%) the treatment option was best supportive care 
and/or referral to specialist palliative care i.e. no primary surgery, 
radiotherapy, or chemotherapy. There were significant (χ2,p<0.001) 
between centre differences in the frequency of supportive/palliative care 
only with 10.8% (32/265) of patients in Aberdeen, 36.8% (50/136) in 
Dunfermline, 22.5% (64/285) in Glasgow and 22.0% (36/164) patients in 
Inverclyde receiving supportive/palliative supportive care (Table 4.8 
model 1). Univariable analyses revealed that the likelihood of 
supportive/palliative care was increased by increasing age (mean 75.1 
years 95%CI 73.8-76.4 vs. 69.1 (68.4-69.9), t test p<0.001), a failure to 
make a histological diagnosis (SCLC 7.8%, NSCLC 13.7%, no histological 
diagnosis 45.9%), decreasing performance status (active supportive care 
for PS 0/1 7.0% vs. 32.9% for PS 2/3/4, χ2,p<0.001), increasing serum CRP 
and creatinine, decreasing albumin and increasing severity scores for 
congestive cardiac failure, cerebrovascular disease, dementia, renal 
impairment, and peripheral vascular disease. The decision to manage a 
patient with best supportive/palliative care was not associated with sex, 
socio-economic status, COPD, IHD, diabetes nor alcohol history. 
Multivariable modeling demonstrated that even after adjustment for 
multiple factors, between centre differences persisted (but not between 
Inverclyde and Aberdeen) and in each centre the decision to treat with 
best supportive/palliative care was associated with age, performance 
status, dementia severity, and extensive small cell lung cancer (Table 4.8, 
model 2). 
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Table  4.8 Results of univariable analysis relating decision to treat by 
best supportive/palliative care to centre (model 1). Model 2 outlines 
the results of multiple logistic regression modeling relating decision to 
treat by best supportive/palliative care to centre, age, dementia 
comorbidity score, performance status, tumour stage, and tumour 
histology. 
 
 Model 1 Model 2 
 Odds ratio (95% 
CI) 
p value Odds ratio (95% 
CI) 
p value 
Aberdeen        (n=32) 1  1  
Dunfermline    (n=50) 4.82 (2.90-7.99) <0.001 3.66(1.97-6.78) <0.001 
Glasgow          (n=64) 2.40 (1.51-3.80) <0.001 1.79(1.04-3.09) 0.036 
Inverclyde       (n=36) 2.33 (1.38-3.92)   0.001 1.20(0.66-2.18) 0.55 
     
Age (years)     
<60            (n=19)   1 <0.001* 
    60-70         (n=37)   1.24(0.54-2.83)  
    70-80         (n=100)   2.14(0.99-4.61)  
>80            (n=72)   3.91(1.73-8.82)  
     
Dementia (severity score)     
     0          (n=192)   1 0.003* 
     1          (n=16)   4.04(1.50-10.9)  
     2          (n=10)   3.92(1.05-14.6)  
     3          (n=10)   3.38(0.77-14.8)  
     
Performance status      
    0           (n=12)   1 <0.001* 
    1           (n=39)   2.07(0.67-6.38)  
    2           (n=62)   4.40(1.44-13.4)  
    3           (n=89)   19.2 (6.2-58.8)  
    4           (n=26)   60.4 (14.1-259)  
     
NSCLC stage I/II (n=26)   1  
NSCLC stage III  (n=50)   0.65 (0.33-1.28) 0.21 
NSCLC stage IV(n=122)   1.23 (0.65-2.30) 0.53 
SCLC limited     (n=4)   0.44 (0.11-1.79) 0.25 
SCLC extensive  (n=8)   0.32 (0.11-0.91) 0.032 
No histology      (n=9)   0.77 (0.29-1.99) 0.58 
 
 
*: p value for trend across categories 
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4.4 Discussion 
 
In this study we have prospectively collected data from 882 patients newly 
diagnosed with lung cancer in four Scottish centres. Within each centre 
the patients were consecutive and thus representative of the local 
population and medical practice. Our hypothesis was that variations in 
population demographics such as socio-economic status, performance 
status, stage at presentation, comorbidity and age determined the ability 
to deliver optimal standard therapy. The aim was to assess variations in 
practice between the four Scottish centres and possible causes for this 
such as demographics, age and comorbidity. A number of differences were 
identified between centres. These included investigation, treatment 
(surgical rates), patient age, tumour histology, stage, smoking history, 
socio-economic profile, ventilatory function and performance status. 
These differences may, in some part, explain the variations in practice 
seen in Scotland and we have attempted to characterise the very complex 
relationship between them. 
 
Much of the variation in the initial treatments delivered may be accounted 
for by differences in comorbidity and patient choice. This is especially the 
case for those who decline surgical intervention. For supportive/ palliative 
care (the decision not to offer active anti-cancer therapy) between centre 
differences persisted after adjustment for tumour factors, demographics 
and comorbidities. The treatment rates shown in this chapter are 
generally unexpectedly low with surgical resection rates under 8% and 
palliative chemotherapy less than 10%. This was noted at the time of this 
aspect of the work and the data reanalyzed. These rates are inaccurately 
low due to coding errors, which are rectified in later chapters of the 
thesis. 
 
Declining PS has been shown to correlate well with poorer survival 
(Radzikowska et al., 2002; Ludbrook et al., 2003). It is difficult to assess if 
comorbidity represents a separate predictive entity for treatment choice 
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or is simply a surrogate for performance status. The multivariable 
modeling indicated that whilst performance status is strongly associated 
with treatment delivered, the presence of co-existing comorbidities was 
additionally associated with treatment differences. Thus co-morbidities 
not only contribute to performance status but also have additional 
associations with treatment selection. In our study, predictors of declining 
performance status included increasing severity of a number of 
comorbidities, age, lower socio-economic status and specific geography 
(primarily Glasgow and Inverclyde).  
 
The rate of decline in PS has never previously been explored. In 
multivariable analysis this rate has been shown to be related to increasing 
age, lower socio-economic group, several comorbid factors and tumour 
stage. However this assessment was retrospective and it has not been 
validated. The decline in PS, independently associated with socio-
economic status within individual cities, probably reflects social trends in 
psychosocial factors influencing health e.g. diet, housing and social 
support. This decline in performance status also highlights the need for 
patients, particularly in lower socio-economic classes, to be seen and 
assessed early on in their disease before they deteriorate to a level where 
radical treatment is inappropriate. The results of this study suggest that 
the striking differences in deprivation seen between centres and generally 
within Scotland, in comparison to the remainder of the United Kingdom 
(Office for National Statistics, 2006; ISD, 2009; Gregor et al., 2001; 
Janssen-Heijnen et al., 1998) may be a contributory factor to the 
observation that Scottish patients with lung cancer have a poorer outcome 
in a global setting. 
 
Surgical resection rates are closely associated with cure for NSCLC (SIGN, 
2005), and the identification of factors influencing this, especially co-
morbidities, were a primary study aim. The mean surgical resection rate in 
this study was 6.3% with a range from 5.5% to 7.4%, these figures are 
similar to those reported by a Cancer Registry in the South East of England 
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that reported a median resection rate of 6% with a range of 4 – 10% (Jack 
et al., 2003). In the present study socio-economic status was not 
associated with the likelihood of patients declining surgery. This contrasts 
with published studies that suggest lower socio-economic status patients 
are more likely to decline surgery (Mitchell et al., 2003). COPD was the 
only comorbid factor to persist once multi-variable analysis, including 
performance status, had been performed. The available literature 
supports the assertion that comorbidity is detrimental to outcome. 
However these studies have not assessed comorbidity in any significant 
detail (Birim et al., 2005; Imperatori et al., 2006) 
 
The decision to offer best supportive/palliative care rather than active 
anticancer therapy clearly differed between centres, even after 
multivariable analysis. This is likely to reflect physician’s choice using 
different criteria to determine treatment choice for a patient and it is 
notable that in this study the centre with the lowest rate of initial 
decision to offer best supportive/palliative care had the highest rate of 
chemotherapy for locally advanced/metastatic NSCLC. The present study 
is consistent with previous studies suggesting that comorbidity appears to 
influence treatment choice and potentially affect outcome, but adds to 
the literature by identifying relevant individual comorbidities and 
demonstrating dose response associations (Potosky et al., 2004; Earle et 
al., 2000; Extermann, 2000; Charlson et al., 1987; Tammemagi et al., 
2004; Janssen-Heijnen et al., 2004; Colinet et al., 2005). 
 
In an attempt to try to assess the reasons for differences in treatment and 
outcome within lung cancer in Scotland, this early data has shown some 
interesting differences between centres in relation to patient 
characteristics and treatment. We believe that one of the strengths of this 
study is that the study population is representative of the local population 
of people presenting with lung cancer because the centralised system of 
free universal healthcare in Scotland ensures that most people with 
suspected lung cancer are referred directly to Respiratory Physicians, in 
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addition comparisons of data submitted centrally from lung cancer MDTs 
with Cancer Registry data confirms that Respiratory Physicians investigate 
in excess of 90% of people with lung cancer in Scotland (MCN, Personal 
Communication). We suspect that the 10% of patients not investigated by 
Respiratory Physicians are relatively elderly, frail with advanced cancer 
diagnosed and managed at home by General Practitioners and those 
diagnosed at post-mortem. The primary outcome of interest was the initial 
treatment option decided by the MDT and given that, the clinician 
responsible for instigating the treatment agrees upon this decision, then it 
is almost certain that the treatment option was initiated. A limitation of 
this study is that because of relative small patient numbers it was not 
possible to analyse the factors influencing some of the more complex 
combined modality treatment decisions e.g. neo-adjuvant chemotherapy, 
sequential chemotherapy and radical radiotherapy, furthermore for 
pragmatic reasons it was not possible to ascertain whether the second part 
of these treatment options were actually commenced and if not why not. 
Such considerations may have contributed to the low rates of radical 
radiotherapy reported. A further limitation of this study is that we do not 
yet have survival data on the subjects and therefore cannot relate our 
observations on comorbidity to survival. We are currently investigating the 
possibility of using centrally collected data to address this. 
 
The important message of this study is that is scientifically unsound to 
compare crude data from centres or countries and conclude that variations 
entirely reflect differences in practice. Whilst it is common practice to 
adjust such comparative data for sex, age, tumour and in some instances 
indirect measures of comorbidity (days in hospital in previous five years) 
our study highlights the need to adjust for other factors such as patient 
choice, comorbidity and performance status. The present study suggests 
that adjustment of comparative data for variation in performance status is 
insufficient and further adjustment for specific and quantified co-
morbidities should be carried out, as comorbidity appears to have an 
independent impact upon between centre differences. Even so, whilst the 
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present study highlights the importance of variation in comorbidity, 
performance status, and tumour stage there is still evidence of between 
centre differences in practice suggesting variation in clinical practice. 
 
Previous studies have shown that Scotland (in particular the West of 
Scotland) suffers from significantly higher rates of many comorbid diseases 
such as Ischaemic Heart Disease (Mitchell et al., 2005), COPD (Thorax, 
2004) and Alcoholism (Emslie et al., 2009). The present study suggests that 
the combination of these comorbidities and social deprivation is especially 
disadvantageous, not only influencing the rate at which performance 
status deteriorates in the six months prior to presentation, but 
additionally affecting the treatment options available to the assessing 
physician. The particularly adverse combination of chronic ill-health and 
social deprivation might explain the significantly poorer performance 
status, lower active treatment rates and poorer survival seen for certain 
centres in Scotland.  
 
This study has identified many significant between centre differences 
within Scotland. We believe this to be the first study to identify non-
tumour factors independent of performance status that together limit the 
ability to deliver radical, possibly curative, therapy to our lung cancer 
population. It is only by identifying such factors that we can hope to 
address the significant health inequalities seen across the four centres and 
in the wider population and begin to improve upon the relatively poor 
outlook for the majority of Scottish lung cancer patients. 
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CHAPTER 5: COMORBIDITIES IN LUNG CANCER: 
PREVALENCE, SEVERITY AND LINKS WITH SOCIO-
ECONOMIC STATUS AND TREATMENT. 
 
5.1 Introduction 
 
Lung cancer remains the commonest cause of cancer related death in 
Scotland (Gregor et al., 2001). Survival lags significantly behind much of 
Western Europe and the United States (Gregor et al., 2001; Janssen-
Heijnen et al., 1998). Many causes for this have been suggested including 
late presentation, the impact of comorbidity and lower treatment rates 
(Berrino et al., 2007; Horner et al., 2009). Surgical resection rates within 
Scotland are around 12% compared to figures often quoted as above 20% 
within Europe and the USA (Fry et al., 1999; Laroche et al., 1998; Cartman 
et al., 2002; Damhuis et al, 1996). Scotland frequently has lower recorded 
rates for both chemotherapy and radiotherapy. Patients in Scotland often 
present late (around 40 -50% will present with stage IV disease (Birring et 
al., 2005) and have significant comorbidity.  
 
In our own previously published work, the prevalence of comorbidity was 
significant with 44% of patients having Chronic Obstructive Pulmonary 
Disease and 27% Ischaemic Heart Disease (Grose et al., 2011). Comorbidity 
has previously been shown to have an adverse impact upon available 
treatment options and subsequent outcome both in cancer in general and 
specifically within lung cancer (Potosky et al., 2004; Earle et al., 2000; 
Extermann, 2000; Charlson et al., 1987; Tammemagi et al., 2004; Janssen-
Heijnen et al., 2004; Colinet et al., 2005; Birim et al., 2005; Imperatori et 
al., 2006; Asmis et al., 2008; Erridge et al., 2009; Grose et al., 2011) and 
it is likely that poorer outcomes in Scotland are due to a complex mixture 
of these factors.  
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There are few studies on the impact of comorbidity in lung cancer (Grose 
et al., 2011). Of these only one study used a tool specifically designed for 
lung cancer(Colinet et al., 2005). Most studies use the Charlson Co-
morbidity Index, which was designed to assess comorbidity in patients with 
breast cancer (Charlson et al., 1987). In none of these studies is the grade 
or severity of disease fully assessed and, because of improved treatment 
options for some of the comorbid conditions (e.g. HIV/AIDS), the 
weightings given to these comorbidities may be out dated. Potential 
selection bias is also an issue as some of these studies only deal with 
operable patients. In addition, information on comorbidities is poorly 
recorded in routinely collected audit and cancer registry data and thus 
little is known about its characteristics among lung cancer patients in 
Scotland.  
 
We know that treatments offered to patients with lung cancer in Scotland 
show inter-centre variability(Grose et al., 2011) (Tables4.1+4.2). However 
we do not know the reason(s) for this. The aim of our study was to 
prospectively describe the prevalence and severity of comorbidities in 
patients newly diagnosed with lung cancer. In addition we wished to assess 
the relationship between presence and severity of comorbidity with 
patient demographics, including a proxy for socioeconomic status, and the 
treatment offered. 
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5.2 Methods  
 
Previously described in chapter 3 
 
 
 
5.3 Statistical Analysis 
 
 
All statistical testing was conducted at the 5% level. Unless otherwise 
stated, medians and interquartile range (IQR) are used. Where appropriate 
the chi-squared test for trend was used to assess for statistically 
significant differences, otherwise the Pearson chi-squared test was used. 
Statistically significant differences were set at p ≤ 0.05. 
 
Statistical analyses were performed using SPSS v19.0 (SPSS Inc., Chicago, 
IL) 
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5.4 Results 
 
Demographics 
 
882 patients were included in the study, comprising 297 from Aberdeen, 
136 from Dunfermline, 285 from Glasgow, and 164 from Inverclyde. The 
ages ranged from 31 to 94 (median 72) and 487 (55%) were male. Baseline 
characteristics are previously described in Chapter 4. 
 
24.5% of patients were diagnosed on the basis of clinical examination and 
radiological investigations alone, without histological evidence. This 
compares favourably with the National Lung Cancer Audit data, which had 
a median rate of 37% (Rich et al., 2011) of patients who did not have 
histological confirmation of lung cancer. We did not look at sub-groups of 
NSCLC histology. 
 
Comorbidity 
 
In total 868 patients had their full comorbidity recorded. Comorbidities 
were found in 758 (87.3%) of patients at the time of diagnosis with lung 
cancer (Table 5.2). Only 110 (12.7%) patients had no comorbidity. Two or 
more comorbidities were found in 557 (64.2%) patients; 347 (40.0%) had 
three or more comorbidities and 4 (0.5%) had as many as 8 (Figure 5.1). 
The most frequent and most severe comorbidity was weight loss, which 
occurred in 53% of patients and had a mean score of 1.20.COPD was the 
next commonest comorbidity, present in 43% of patients and with a mean 
severity score of 0.76, followed by renal impairment (28%, mean 0.40) and 
IHD (27%, mean 0.36) (Table 5.1). The cumulative severity score in those 
with comorbidities ranged from 1-15 (mean 3.8 and median 3.0) 
 
The most common co-existing diseases were weight loss and COPD (215 
cases, 24% of 882 patients), weight loss with renal impairment (164 cases, 
19%), COPD with renal impairment (154 cases, 17%), weight loss with IHD 
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(144 cases, 16%) and COPD with IHD (124 cases, 14%). The numbers of 
patients with aetiologically similar cardiovascular morbidities was low, 
with IHD and CVA concurring in 32 cases (4%), IHD and PVD in 37 cases (4%) 
and PVD and CVA in 14 cases (2%).The commonest co-existing diseases 
which both had grade 3 severity were severe weight loss with severe COPD 
(20 cases, 2%), severe renal impairment (9 cases, 1%) or severe IHD (9 
cases, 1%) (Table 5.2). 
 
Table 5.1. Distribution of comorbidities among 868 newly diagnosed 
lung cancer patients. 
 
                Severity n (%) 
Comorbidity 
(missing 
data / %) 
0 1 2 3 Mean 
Weight loss 
(3/ 0.3%) 
416 (47%) 131 (15%) 74 (8%) 258 (29%) 1.20 
 
COPD 
(9/ 1%) 
494 (57%) 146 (17%) 180 (21%) 53 (6%) 0.76  
 
Renal 
impairment 
(7/ 0.8%) 
634 (72%) 145 (17%) 79 (9%) 17 (2%) 0.40  
 
IHD 
(4/ 0.5%) 
645 (73%) 165 (19%) 50 (6%) 18 (2%) 0.36   
 
CCF 
(4/ 0.5%) 
759 (86%) 84 (10%) 31 (4%) 4 (0.5%) 0.18  
Other 
Malignancy 
(3/ 0.3%) 
755 (86%) 95 (11%) 28 (3%) 1 (0.1%) 0.18  
Alcohol xs 
(5/ 0.6%) 
774 (88%) 65 (7%) 20 (2%) 18 (2%) 0.18  
Diabetes 
(5/ 0.6%) 
776 (88%) 66 (8%) 32 (4%) 3 (0.3%) 0.16   
 
CVA 
(4/ 0.5%) 
800 (91%) 52 (6%) 18 (2%) 8 (1%) 0.13   
PVD 
(4/ 0.5%) 
800 (91%) 45 (5%) 27 (3%) 6 (0.7%) 0.13  
 
Dementia 
(4/ 0,5%) 
827 (94%) 24 (3%) 14 (2%) 13 (1%) 0.10  
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Figure 5.1. Histogram showing number of comorbid conditions per 
patient.  868 lung cancer patients in 4 Scottish centres, 2005-08. 
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Table 5.2. Concurrence between individual comorbid conditions. 868 
lung cancer patients in 4 Scottish centres, 2005-08. 
(Left of diagonal for any grade. Right of diagonal for grade 3 of both conditions) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Comorbidity 
 
 
Comorbidity 
 Weight 
loss 
COPD Renal 
impairment 
IHD CCF Other 
malignancy 
Alcohol 
XS 
Diabetes CVA PVD Dementia 
Weight loss  20 9 9 2 0 5 0 4 2 4 
COPD 215  0 0 0 0 1 0 0 0 0 
Renal 
impairment 
164 154  0 0 0 0 0 0 0 0 
IHD 144 124 83  3 0 0 0 0 0 0 
CCF 76 62 43 90  0 0 0 0 0 0 
Other 
Malignancy 
73 61 46 39 22  0 0 0 0 0 
Alcohol xs 64 66 61 25 18 18  0 0 0 1 
Diabetes 56 47 47 44 26 24 24  0 0 0 
CVA 50 37 32 32 17 14 13 13  0 0 
PVD 43 46 35 37 20 16 16 18 14  0 
Dementia 42 33 33 24 12 12 17 15 18 10  
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Using the cumulative comorbidity scoring index (Table 5.3) we found that 
411 (47.4%) of patients with lung cancer had moderate (278 (32.0%) or 
severe comorbidities (133 (15.3%). 
 
Table 5.3. Cumulative comorbidity scoring index. 868 lung cancer 
patients in 4 Scottish centres, 2005-08. 
 
 
Range of 
cumulative 
comorbidity 
score 
Group Number of 
patients 
Percentage of 
patients 
 
 
0 
 
 
 
Nil 
 
 
110 
 
 
 
12.7% 
 
1-3 
 
 
 
Low 
 
347 
 
40.0% 
 
4-6 
 
 
Moderate 
 
 
278 
 
32.0% 
 
 
≥ 7 
 
Severe 
 
133 
 
15.3% 
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Relationship between demographics and comorbidity (Table 5.4) 
 
The presence of comorbidity in patients with lung cancer varied 
significantly between the 4 centres. The prevalence of severe co-
morbidity (index score of 3) was three times higher in patients treated in 
Dunfermline than the other three centres (p <0.001 Pearson chi-squared 
test) 
 
Relationship between socio-economic status and comorbidity (Table 5.4) 
 
Significant variations in the level of co-morbidity between the relative 
socio-economic groups were seen. The most deprived patients had 
increased levels of comorbidity in comparison with those from more 
affluent backgrounds (p=0.026 Pearson chi-squared test) 
 
Relationship between cancer stage and comorbidity (Table 5.5) 
 
The presence of comorbidity did not appear to be associated with stage of 
disease for either NSCLC (p=0.406) or SCLC (p=0.348) 
 
Relationship between treatments offered for NSCLC patients and 
comorbidity (Table 5.4) 
 
Among patients with NSCLC, there were significant associations between 
comorbidities and treatment.  For NSCLC with early stage disease disease, 
patients offered surgery had lowest comorbidities scores, indicating fewer 
and less severe comorbidities, while those not offered curative treatment 
had most severe comorbidity scores (p = 0.006 Chi-square test for trend).  
Similarly, the least active palliative treatments were offered to those 
patients with most severe comorbidities (p<0.001 Pearson chi-squared 
test).   
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Table 5.4. The relationship between comorbidity grouping, 
demographics, socio-economic status, stage and treatment. 
 
                 Comorbid group  % (n) 
 Nil Low Moderate Severe 
 
Centre (n = 882) (p<0.001) 
Aberdeen (297) 21%  41% 27% 11% 
Glasgow       (285)   8% 44% 35% 13% 
Inverclyde  (164) 14% 44% 30% 12% 
Dunfermline (136) 3% 21% 41% 35% 
 
Socio-economic status (quintile) (n=868) (p=0.026) 
1 (Most deprived) 
(265) 
11% 42% 33% 14% 
2 (126) 14% 33% 36% 17% 
3 (248) 8% 43% 34% 15% 
4 (169) 18% 35% 31% 16% 
5 (60) 22% 48% 18% 12% 
 
Stage NSCLC  (n = 525) (p=0.406) 
I       (65) 17% 49% 26% 8% 
II     (43) 7% 44% 33% 16% 
IIIa (48) 6% 48% 35% 11% 
IIIb (138) 14% 46% 31% 9% 
IV    (231) 15% 44% 25% 16% 
 
Stage SCLC (n = 115)            (p=0.348) 
Limited (33) 25% 39% 21% 15% 
Extensive (82) 15% 32% 35% 18% 
 
 
Early Stage NSCLC (n=156)  (p=0.006) 
 
Surgery (55) 18% 49% 29% 4% 
Radical Radiotherapy 
(32) 
9% 47% 34% 10% 
No curative  
Option (69) 
6% 46% 30% 18% 
 
Advanced Stage NSCLC (n = 362) (p=0.001) 
Palliative  
Chemotherapy (176) 
18% 52% 25% 5% 
Palliative 
radiotherapy (88) 
9% 36% 36% 19% 
Supportive care (98) 
 
11% 39% 24% 26% 
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5.5 Discussion 
 
We have found a high prevalence of comorbidity at presentation in 
patients with lung cancer. Comorbidities most frequently identified are 
weight loss (which was found in over 50% of patients), COPD, renal 
impairment and IHD. Most patients have at least one comorbidity and two 
thirds had two or more Given that most patients were current or ex 
smokers, fewer than expected had cardiovascular comorbidities. However, 
our findings are consistent with recent British Heart Foundation reports 
(British Heart Foundation, 2009). The overall severity of comorbidity was 
associated with socio-economic status and treatment centre. Importantly 
comorbidity status at presentation was associated with the treatment 
offered. 
 
Treatment options for lung cancer, in particularly for advanced NSCLC, 
have significantly increased over the past decade (NICE 121, 2011) with a 
resultant improvement in survival. The trial data to support the use of 
such treatments is based on patients with good performance status. 
Significant comorbidity usually excludes a patient from enrolment into 
therapeutic clinical trials.  We have demonstrated that worsening 
comorbidity detrimentally affects the likelihood of a patient being offered 
active treatment. It would seem logical to suggest that this is highly likely 
to have a negative impact upon survival. 
 
We are not aware of any published studies that combine both the number 
and severity of comorbidities into a simple index. In addition no similar 
work has so clearly demonstrated a link between comorbidity, 
socioeconomic status and treatment offered. A recent study by Wang et al 
(2012) using the Charlson Comorbidity Index suggested that age rather 
than comorbidity was the most significant negative predictor of 
treatment. It did not look at outcomes or survival. The Adult Comorbidity 
Evaluation 27 (ACE-27) tool, initially validated in head and neck cancer 
was used in a prospective study including over 17,000 patients a large 
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cohort of whom had lung cancer (Piccirillo et al., 2004). This showed that 
worsening co-morbidity significantly impacted negatively on survival, 
however sub-group analysis identified comorbidity as having the least 
prognostic information in lung cancer patients.  
 
The major limitation of this study is the lack of survival data currently 
available. Although the cumulative comorbidity index was found to be 
associated with, centre, socio-economic status and active treatment rates, 
suggesting it has some validity, clearly significantly more work will be 
required to demonstrate a formal link with survival. This work is currently 
underway. 
 
The important role that comorbidity has in affecting outcomes in lung 
cancer is beginning to be noted and the inclusion of basic data within the 
English National Lung Cancer Audit (NLCA) is welcomed. However we 
believe that more detailed recording is imperative to improve the 
understanding we have for comorbidity and the impact it has on lung 
cancer outcomes. Our study goes someway towards addressing this, 
currently unmet, need. 
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CHAPTER 6: SIMPLE AND OBJECTIVE PREDICTION OF 
SURVIVAL IN PATIENTS WITH LUNG CANCER; STAGING 
THE HOST SYSTEMIC INFLAMMATORY RESPONSE. 
 
6.1 Introduction 
 
Within Scotland lung cancer remains the commonest cause of cancer 
related death (Berino et al., 2007).  The prognosis is bleak with the 
median survival in advanced disease around four months from diagnosis 
(Berino et al., 2007).  Survival compares unfavourably with other European 
countries and USA (Berino et al., 2007; Janssen-Heijnen et al. 1998). It has 
often been felt that the Scottish lung cancer population has more 
comorbidity with poorer performance status thus presenting fewer 
tolerable therapeutic options.   
 
It is difficult to quantify the complex nature of patient frailty to provide a 
degree of objective assessment of fitness (Maltoni et al., 2005) and as a 
result prediction of survival in patients diagnosed with lung cancer 
remains problematical.  Currently, prognosis is based upon a combination 
of stage of disease and performance status although other factors such as 
weight loss have been identified in the advanced cancer setting (Martin et 
al., 2010; Glare et al., 2004; Gripp et al., 2007). However, these host 
factors (weight loss and performance status) included in clinical decisions 
are recognized to be subjective in nature. 
 
Recent work shows that the effect of systemic inflammation is detrimental 
in terms of outcome in cancer in general (McMillan, 2009; Proctor et al., 
2011) and in lung cancer specifically (Wilop et al., 2006; Kock et al., 2009; 
Gagnon et al., 2010; Arrieta et al., 2010; Forrest et al., 2004; Forrest et 
al., 2005; Brown et al., 2007; Leung et al., 2012). The combination of C 
reactive protein and albumin when combined to calculate the modified 
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Glasgow Prognostic Score (Table 6.1) has been previously been validated 
as an independent predictor of survival (McMillan. 2014). 
 
The aim of the present study was to examine the clinical utility of this 
established objective marker of the systemic inflammatory response, the 
modified Glasgow Prognostic Score (mGPS), as the basis of risk 
stratification in patients with lung cancer. 
 
 
Table 6.1 The Glasgow Prognostic Scores  
 
 Score 
Glasgow Prognostic score (GPS)  
CRP ≤ 10mg/l and albumin ≥ 35g/l 0 
CRP > 10mg/l or albumin < 35g/l 1 
CRP > 10mg/l and albumin < 35g/l 2 
  
modified Glasgow Prognostic Score 
(mGPS) 
 
CRP ≤ 10mg/l and albumin ≥ 35g/l 0 
CRP ≤ 10mg/l and albumin < 35g/l 0 
CRP > 10mg/l 1 
CRP > 10mg/l and albumin < 35g/l 2 
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6.2 Methods 
 
Previously discussed in chapter 3 
 
Survival data 
 
Information on date of death was obtained via survival analysis undertaken 
by the Information Service Division (ISD) of NHS Scotland. Death records 
were complete until 1 June 2011, which served as the censor date for 
those alive. 
 
GPS/ mGPS  
 
A venous blood sample was obtained at diagnosis for measurement of CRP 
concentration and albumin.  The coefficient of variation for these methods 
over the range of measurement was less than 5%, as established by routine 
quality control procedures.  The GPS was constructed as previously 
described (Table 6.1) (Forrest et al., 2003; McMillan et al., 2007). In brief, 
CRP more than 10 mg/L and albumin less than 35 g/dl were each given a 
score of 1. The GPS was calculated as 0, 1, or 2. Since hypoalbuminaemia 
alone in the absence of an increased CRP level did not confer a poorer 
cancer-specific survival in all patients with cancer (McMillan et al., 2007), 
the GPS was modified to assign a score of 0 in patients with 
hypoalbuminaemia alone (Table 6.1) (Crumley et al., 2008). 
 
A number of recent studies have supported the use of mGPS in predicting 
outcome both in lung cancer and other tumour types (Wilop et al., 2006; 
Kock et al., 2009; Gagnon et al., 2010; Arrieta et al., 2010; Forrest et al., 
2004; Forrest et al., 2005; Brown et al., 2007; Leung et al., 2012). It was 
our intention to stratify the group by mGPS and then analyse the impact of 
more conventional staging methods such as TNM stage and performance 
status. 
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6.3 Statistics 
 
All statistical testing was conducted at the 5% level so 95% confidence 
intervals (CI) are reported throughout.  Unless otherwise stated, medians 
and interquartile range (IQR) are used.  The survival time defined as the 
number of months from study entry until death or if alive at follow-up 
date, was calculated.  Univariate survival analysis was carried out using 
Kaplan-Meier method and the log rank test.  Survival analysis was carried 
out using the Cox’s proportional-hazards model and hazard ratios (HR) 
were calculated.  Multivariate survival analysis was performed using a 
stepwise backward procedure to derive a final model of the variables that 
had a significant independent relationship with survival.  To remove a 
variable from the model, the corresponding P-value had to be >0.10.  
 
 Statistical analyses were performed using SPSS v19.0 (SPSS Inc., Chicago, 
IL). 
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6.4 Results 
 
In total, 882 patients from a number of different treatment groups were 
included in the study, comprising 297 from Aberdeen, 136 from 
Dunfermline, 285 from Glasgow, and 164 from Inverclyde composing; 59 
patients were excluded from the study due to missing survival data (Figure 
6.1).  Baseline characteristics are previously described in chapter 4.  The 
median age of participants was 72 years old. The majority was male, 
current or ex-smokers, of good performance status with advanced disease 
and had treatment with palliative intent. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1 Flow chart of patient selection process
Surgery	  	  	  54	  patients	  	  
Palliative	  Chemotherapy	  	  	  	  162	  patients	  
Palliative	  Radiotherapy	  	  	  	  158	  patients	  
Excluded	  due	  to	  missing	  survival	  data	  	  (n	  =	  	  59)	  
SCLC	  	  	  	  112	  patients	  
	  	  No	  active	  treatment	  	  	  261	  patients	  	  	  
Radical	  Radiotherapy	  	  	  76	  patients	  	  
All	  patients	  	  (n	  =	  882)	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Most had an elevated mGPS.  The median follow up for survivors was 24.5 
months (4.6 – 40.8).  The median overall survival was 5.6 months (4.8 – 
6.5).  The 12-month survival rate was 30% (SE 2%).  
 
Survival analysis using both GPS and mGPS was undertaken (Figures 6.2 + 
6.3).  Both were highly significantly associated with survival.  Since the 
mGPS has been most extensively validated and readily extrapolated from 
previous work using C-reactive protein alone (McMillan et al., 2009; 
McMillan, 2014) it was used in the remainder of the analysis and to stratify 
the three groups.  
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Figure 6.2 – The relationship between the Glasgow Prognostic Score 
(GPS) (0 – 2, from top to bottom) and survival. GPS 0 vs. 1 (log rank 
p<0.001), GPS 1 vs. 2 (log rank p<0.001)  
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Figure 6.3 – The relationship between the  modified Glasgow Prognostic 
Score (mGPS) (0 – 2, from top to bottom) and survival. mGPS 0 vs 1(log 
rank p<0.001), mGPS 1 vs 2 (log rank p<0.001) 
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The relationship between the mGPS and clinicopathological characteristics 
is shown in Table 6.2.  There were 213 patients in the mGPS score of 0 
group, 290 patients in the mGPS score of 1 group and 218 patients in the 
mGPS score of 2 group.  The mGPS was associated with increasing 
deprivation (p<0.001), pack years smoking (p<0.001), poorer performance 
status (p<0.001), more weight loss (p<0.001), more advanced disease 
(p<0.001), less radical treatment (p<0.001) and poorer survival (p<0.001).   
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Table 6.2 The relationship between the mGPS and clinicopathological 
characteristics in patients with lung cancer  
Demographic                                                mGPS 
 
P value  
(chi-square test) 
0 (n= 213) 1 (n= 290) 2 (n= 218) 
Age (<60/60-69/70-
79/≥80 years) 
33/71/89/28 44/87/119/54 34/57/91/49 0.064 
Sex  Male/Female 115/108 174/130 133/98 0.201 
Centre 
Aber/Dunf/Gla/Inver 
98/10/77/38 146/25/66/67 43/16/126/46 <0.001 
Deprivation 
Most – Least (quintile) 
68/24/71/39/21 75/47/75/77/30 111/21/70/20/9 <0.001 
Smoke (pack years) 
NS/<20/20-60/>60 
21/24/126/37 11/33/177/69 13/21/128/57 0.014 
Performance Status 
0/1/2/3/4 
42/96/60/22/3 26/130/105/40/3 5/51/88/66/21 <0.001 
Weight loss (%) 
0/<5/5-10/>10 
147/24/12/38 146/36/13/109 79/45/33/73 <0.001 
FEV1 (%) 
<80/61-80/40-60/<40 
138/31/45/7 181/48/53/22 130/33/47/17 0.126 
Local Symptoms  
No /Yes 
36/127 18/222 29/137 0.246 
Tumour Stage NSCLC 
I/II/IIIa/IIIb/IV 
32/11/7/38/38 15/19/20/56/84 7/5/12/36/79 <0.001 
Tumour Stage SCLC 
Limited/Extensive 
13/21 10/32 8/18 0.471 
 
Treatment 
 
 
Early Stage 
(Surgery/RT/no 
active) 
 
26/9/38 
 
17/15/43 
 
4/2/18 
 
<0.001 
Advanced Stage 
(Chemo/RT/No 
active) 
 
63/27/49 
 
107/58/55 
 
50/49/75 
 
<0.001 
Survival 
Alive/dead 34/181 16/274 8/211 0.003 
12 month survival % 
(SE) 
46 (4) 16 (2) 14 (3) <0.001 
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The relationship between the clinico-pathological characteristics and 
survival in patients with an mGPS of 0 is shown in Table 6.3.  The median 
survival was 13.2 (11.2 – 18.9) months.  On univariate survival analysis, 
performance status (p<0.001), weight loss (p<0.01), stage of NSCLC 
(p<0.001), radical treatment offered (p<0.01) and palliative treatment 
offered (p<0.05) were all significantly associated with survival.  On 
multivariate analysis, performance status (HR 1.69, 95% CI 1.39-2.06, 
p<0.001), weight loss (HR 1.18, 95% CI 1.04-1.33, p=0.009), stage of NSCLC 
(HR 1.06, 95% CI 1.01-1.23, p=0.017) and palliative treatment offered (HR 
1.30, 95% CI 1.08-1.55, p=0.004) were independently associated with 
survival. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   100	  
Table 6.3 The relationship between parameters and survival in patients 
with mGPS = 0 (n=213) 
 
Parameter Patients                     Univariate           Multivariate 
 N HR (95%CI) p-value HR (95%CI) p-value 
 
Age  (<60/ 60-69/70-
79/≥80 years) 
 
33/71/89/28 
 
1.16(0.98-1.37) 
 
0.077 
 
Sex    Male 115 1    
 Female 108 0.81(0.61-1.09) 0.169   
Centre    Aberdeen 98 1 0.068   
Dunfermline 10 2.72(1.40-5.29)    
Glasgow 77 1.00(0.72-1.41)    
Inverclyde 38 1.13(0.75-1.70)    
Deprivation (Most 
deprived = 1, Least 
Deprived  = 5) 
1/2/3/4/5 
 
 
 
68/24/71/39/21 
 
 
 
0.94(0.85-1.05) 
 
 
 
0.299 
  
 
Smoking history (NS = never smoker, otherwise pack years) 
   NS/<20/20-60/>60 21/24/126/37 0.93(0.77-1.12) 0.467   
 
Performance Status 
    0/1/2/3/4 42/96/60/22/3 1.76(1.47-2.11) <0.001 1.69(1.39-2.06) <0.001 
 
Weight loss (%Body weight) 
 
   0/<5/5-10/>10 147/24/12/38 1.21(1.08-1.37) 0.002 1.18(1.04-1.33) 0.009 
 
FEV1 (%) 
 
>80/80-60/59-40/<40 138/31/45/7 0.94(0.80-1.12) 0.515   
 
Local Symptoms 
    No/Yes 36/127 1.38(0.91-2.09) 0.124   
 
Stage 
NSCLC  
I/II/IIIa/IIIb/IV 
32/11/7/38/38 
 
1.38(1.25-1.53) 
 
<0.001 
 
1.06(1.01-1.23) 0.017 
SCLC 
Limited/Extensive 
13/21 1.05(0.97-1.14) 0.228   
 
 Treatment 
Early Stage 
BSC/Surgery/RT 
 
37/26/8 
 
0.61(0.48-0.78) 
 
0.001 
  
Advanced Stage 
Chemo/RT/BSC 
 
59/27/47 
 
1.22(1.01-1.46) 
 
0.039 
 
1.30(1.08-1.55) 
 
0.004 
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The relationship between the clinico-pathological characteristics and 
survival in patients with an mGPS of 1 is shown in Table 6.4.  The median 
survival was 6.1 (4.9 – 7.3) months. On univariate survival analysis, 
decreased age (p<0.01), performance status (p<0.001), weight loss 
(p<0.01), stage of NSCLC (p<0.001) and radical treatment offered 
(p<0.001) were significantly associated with survival.  On multivariate 
analysis, performance status (HR 1.81, 95% CI 1.55-2.13, p<0.001), stage 
of NSCLC (HR 1.08, 95% CI 1.03-1.13, p<0.01) and radical treatment 
offered (HR 0.70, 95% CI 0.52-0.94, p<0.05) were independently associated 
with survival. 
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Table 6.4 The relationship between parameters and survival in patients 
with mGPS = 1 (n=290) 
 
 
Parameter Patients                     Univariate           Multivariate 
 N HR (95%CI) p-value HR (95%CI) p-value 
Age 
<60/ 60-69/70-79/≥80 33/71/89/28 1.24(1.09-1.40) 0.001  
 
Sex 
 
      Male 174 1 0.171   
      Female 130 0.84(0.66-1.08)    
 
Centre 
      Aberdeen 145 1 0.425   
Dunfermline 23 0.89(0.55-1.43)    
Glasgow 55 0.99(0.72-1.36)    
      Inverclyde 
 
67 1.23(0.92-1.66)    
 
Deprivation(Quintile) 
(Most deprived = 1, 
Least Deprived  = 5) 
    
 
1/2/3/4/5 75/47/75/77/30 0.99(0.90-1.08) 0.777   
 
Smoking history (NS = never smoker, otherwise pack years) 
   NS/<20/20-60/>60 11/33/177/69 1.02(0.86-1.22) 0.792   
 
Performance Status 
    0/1/2/3/4 26/130/105/40/3 1.83(1.57-2.14) <0.001 1.81(1.55-2.13) <0.001 
 
 
Weight loss (%Body weight) 
 
   0/<5/5-10/>10 181/48/53/22 1.15(1.06-1.25) 0.001   
 
FEV1 (%) 
 
>80/80-60/59-40/<40 138/31/45/7 0.94(0.83-1.06) 0.313   
 
Local Symptoms 
    No/Yes 18/222 1.60(0.91-2.80) 0.105   
 
Stage 
NSCLC  
I/II/IIIa/IIIb/IV 
15/19/20/56/84 1.31(1.19-1.45) 
 
<0.001 
 
1.08(1.03-1.13) 0.002 
SCLC 
Limited/Extensive 
10/32 0.51(0.23-1.11) 0.091   
 
 Treatment 
Early Stage 
Best Supportive Care 
(BSC)/Surgery/RT 
43/17/15 0.55(0.41-0.72) <0.001 0.70(0.52-0.94) 0.017 
Advanced Stage 
Chemo/RT/BSC 
107/58/55 
 
1.07(0.90-1.26) 0.436   
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The relationship between the clinico-pathological characteristics and 
survival in patients with an mGPS of 2 is shown in Table 6.5.  The median 
survival was 2.1 (1.5 – 2.7) months.  On univariate survival analysis, centre 
(p<0.01), performance status (p<0.001), weight loss (p<0.001), stage of 
NSCLC  (p<0.001) and radical treatment offered (p<0.01) were significantly 
associated with survival.  On multivariate analysis, only performance 
status (HR 1.44, 95% CI 1.21-1.71, p<0.001) and weight loss (HR 1.13, 95% 
CI 1.00-1.28, p<0.05) were independently associated with survival. 
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Table 6.5  The relationship between parameters and survival in 
patients with mGPS = 2 (n=218) 
 
Parameter Patients                     Univariate           Multivariate 
 N HR (95%CI) p-value HR (95%CI) p-value 
Age 
<60/60-69/70-79/≥80 34/57/91/49 1.13(0.98-1.30) 0.084  
 
Sex 
 
      Male 133 1 0.136   
      Female 98 0.81(0.61-1.07)    
 
Centre 
      Aberdeen 43 1 0.002   
Dunfermline 16 1.71(0.95-3.06)    
Glasgow 114 0.64(0.45-0.92)    
      Inverclyde 
 
45 0.88(0.57-1.35)    
 
Deprivation(Quintile) 
(Most deprived = 1, 
Least Deprived  = 5) 
    
 
1/2/3/4/5 111/21/70/20/9 1.05(0.94-1.17) 0.408   
 
Smoking history (NS = never smoker, otherwise pack years) 
   NS/<20/20-60/>60 13/21/128/57 0.83(0.69-1.00) 0.062   
 
Performance Status 
    0/1/2/3/4 5/51/88/66/21 1.51(1.30-1.76) <0.001 1.44(1.21-1.71) <0.001 
 
Weight loss (%Body weight) 
 
   0/<5/5-10/>10 79/45/33/73 1.25(1.11-1.40) <0.001 1.13(1.00-1.28) 0.047 
 
FEV1 (%) 
 
>80/80-60/59-40/<40 130/33/47/17 0.88(0.77-1.01) 0.073   
 
Local Symptoms 
    No/Yes 29/137 1.51(0.98-2.33) 0.063   
 
Stage 
NSCLC  
I/II/IIIa/IIIb/IV 
7/5/12/36/79 1.32(1.15-1.50) 
 
<0.001 
 
  
SCLC 
Limited/Extensive 
8/18 1.01(0.91-1.12) 0.826   
 
 Treatment 
Early Stage 
BSC/Surgery/RT 
18/2/4 
 
0.52(0.33-0.83) 0.006   
Advanced Stage 
Chemo/RT/BSC 
50/49/75 
 
0.92(0.78-1.10) 0.364   
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The relationship between mGPS, Performance status and survival at 1 year 
is shown in Table 6.6. When used in combination survival at 1 year varied 
from 72% (mGPS 0, PS 0) to 6% (mGPS 2, PS 3). The numbers in the PS 4 
subgroup were too small to calculate accurately a survival rate. 
 
Table 6.6 The relationship between mGPS and PS and 12 month survival 
rate (%, SE).  
 
 
NC not calculated where N<10. 
 
 
 
 
 
 
 
 
                                            mGPS  Total number 
of patients 
PS 0 1 2  
0 72% (7) 50% (10) 20% (18) 71 
1 65% (5) 31% (4) 30% (7) 259 
2 49% (7) 19% (4) 16% (4) 245 
3 9% (6) 5% (4) 6% (3) 122 
4 NC NC NC 20 
Total 
number of 
patients 
212 290 218  
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The relationship between mGPS, TNM stage (NSCLC patients only) and 
survival at 1 year is shown in Table 6.7. Survival varied from 69% (mGPS 0, 
Stage I NSCLC) to 2% (mGPS 2, Stage IV NSCLC). 
 
Table 6.7   The relationship between mGPS and TNM Stage (NSCLC only) 
and 12 month survival rate (%, SE).  
 
 
 
 
NC not calculated where N<10. 
 
 
 
 
 
 
 
                                            mGPS  Total number 
of patients 
Stage 0 1 2  
I 69% (19) 28% (12) NC 62 
II 37% (14) 17% (9) NC 47 
IIIa 20% (13) 42% (10) 0% 53 
IIIb 20% (6) 6% (3) 14% (5) 154 
IV 5% (3) 4% (2) 2% (2) 261 
Total 
number of 
patients 
153 225 173  
	   107	  
To stratify for stage, the relationship between mGPS and PS and survival 
at 3 months for those patients with advanced NSCLC (stage IIIb/IV) is 
shown in Table 6.8. Survival varied from 100% (mGPS 0, PS 0) to 23% 
(mGPS 2, PS3). The number of patients in the PS 4 group was too small to 
accurately calculate survival. 
 
Table 6.8.  The Relationship between mGPS and PS and 3 month 
survival rate  (%, SE) in patients with TNM stage IIIb/IV NSCLC  (n = 
374). 
 
 
 
 
                                         mGPS Total 
number of 
patients 
PS 0       1 2  
0 100% (0) 92% (8) 100% (0) 28 
1 94% (4) 73% (6) 55% (9) 119 
2 65% (11) 62% (7) 43% (8) 105 
3 NC 29%  (11) 23% (8) 55 
4 NC NC NC 7 
 
 
Total 
number of 
patients 
61 134 111  
 
NC not calculated when N <10 
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This group was then further stratified to take into account the treatment 
offered. The relationship between mGPS and PS at 3 months for those 
patients with advanced NSCLC (stage IIIb/IV) undergoing palliative 
chemotherapy is shown in Table 6.9. Survival varied from 92% (mGPS 0, PS 
1) to 50% (mGPS 2, PS 2). The numbers of patients in the PS 0 and 4 groups 
were too small to accurately calculate survival. 
 
 
 
Table 6.9.  The Relationship between mGPS and PS and 3 month 
survival rate  (%, SE) in patients with TNM stage IIIb/IV NSCLC and 
receiving palliative chemotherapy  (n = 138). 
 
 
 
 
                                         mGPS Total 
number of 
patients 
PS 0       1 2  
0 NC NC NC 13 
1 92% (7) 74% (8) 54% (14) 60 
2 NC 69% (12) 50% (16) 33 
3 NC NC NC 12 
4 NC NC NC 0 
 
Total 
number of 
patients 
27 61 30  
 
NC not calculated when N <10 
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6.5 Discussion 
 
The results of the present study show for the first time that, in a large 
cohort of patients with lung cancer and using the mGPS as an objective 
basis for the prediction of survival, significant factors associated with 
survival varied significantly. Only performance status and to a lesser 
extent tumour stage were consistently shown to have independent 
prognostic value.  Furthermore, the combination of the mGPS with either 
performance status or tumour stage effectively stratified the likely 
outcome in these patients.  Therefore, this simple scheme based on 
objective criteria provides a new readily applicable approach to the 
routine clinical evaluation of patients with lung cancer. 
 
In the present study it was of interest that weight loss, a well recognised 
poor prognostic factor, was inconsistently prognostic when included in the 
analysis with mGPS and performance status. This may suggest that much 
of the prognostic value of weight loss is attributable to the activation of 
the systemic inflammatory response and to the progressive loss of lean 
tissue leading to nutritional and functional decline (McMillan, 2009). 
Indeed, activation of the systemic inflammatory response resulted in a 
marked reduction in median survival of 13 months (mGPS 0) to 2 months 
(mGPS 2) independent of treatment received.  This would suggest that the 
allocation of treatment was suboptimal and it may be that treatment 
allocated on a more objective scheme as proposed above will result in 
improved outcomes in all patients. For example, in those patients with 
mGPS of 2, neither stage nor treatment had independent prognostic value 
and therefore it would appear that such poor prognosis patients derive 
little benefit from standard anti-cancer. In particular a very honest 
appraisal of both benefits and toxicities of any treatment should be made 
with the patient irrespective of their tumour stage (MacDonald, 2012). 
However it must be noted that the very small numbers of patients in these 
groups (e.g. only 2 patients underwent surgery and 4 underwent radical 
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radiotherapy) makes it very difficult to interpret and further studies 
looking only at radically treatable patients are advised. 
 
The relationship between poor survival and systemic inflammation (the 
mGPS) remains poorly understood but it is likely to represent an objective 
marker of the chronic activation of the innate immune response with the 
consequent up-regulation of pro-inflammatory cytokines and growth 
factors and the resultant cancer cachexia (Scagliotti et al., 2008; Du Clos 
et al., 2004; Nozoe et al., 2000; Coussens et al., 2002; Abramovitch et al., 
1999; Canna et al., 2008). 
 
It is clear that, in Scotland, lung cancer continues to confer a very poor 
outcome with a median life expectancy of approximately 5 months.  Even 
in early disease (TNM stage I/II NSCLC), with patients undergoing radical 
treatment with an expectation of cure (10 -15% of total number of 
patients within Scotland (Edge et al., 2009)) the 5-year survival is only 
around 30-60% (Edge et al., 2009). The advent of more advanced imaging 
modalities such as PET-CT (SIGN, 2005) has improved detection of occult 
metastasis leading to stage migration and less patients undergoing futile 
radical local treatment.  Nevertheless, the present results highlight the 
importance of also staging the host systemic inflammatory response.  The 
mGPS is a simple, cheap, and reproducible prognostic tool that has been 
shown to be a rational starting point for such work.  
 
Since the initial work, a decade ago the combination of C-reactive protein 
and albumin, the Glasgow Prognostic Score (GPS/ mGPS), has been shown 
to have independent prognostic value in more than 60 studies (>30,000 
patients with cancer).  This prognostic value has been demonstrated in a 
variety of clinical scenarios, in particular primary operable cancer 
(McMillan, 2014) 
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More recently in approximately 2,500 patients (Laird et al., 2013) and this 
present study have demonstrated that the mGPS has also clinical utility, 
together with performance status, in patients with advanced cancer.   
 
In conclusion, the results of the present study confirm the independent 
prognostic value of the mGPS.  In addition, it demonstrates the clinical 
utility of the mGPS combined with performance status to provide more 
objective risk stratification in patients diagnosed with lung cancer. 
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CHAPTER 7: THE IMPACT OF COMORBIDITY UPON 
DETERMINANTS OF OUTCOME IN PATIENTS WITH LUNG 
CANCER.  
 
7.1 Introduction 
 
Within Scotland lung cancer remains the commonest cause of cancer 
related death (Gregor et al., 2001). Survival lags significantly behind much 
of Western Europe and the United States (Gregor et al., 2001; Janssen-
Heijnen et al., 1998). The cause(s) for this are not fully understood but 
are likely to include late presentation, the impact of comorbidity and 
lower treatment rates (Berrino et al., 2007; Horner et al., 2009; Fry et al., 
1999; Laroche et al., 1998; Cartman et al., 2002; Damhuis et al., 1996; 
Birring et al., 2005). Our own, previously published, work has identified 
very high levels of comorbidity within an unselected lung cancer 
population within Scotland (Grose et al., 2011). It has also indicated that 
such comorbidity may play an important part in the decision to offer 
active treatment both in the radical and palliative setting (Grose et al., 
2014). These findings have been supported by a number of studies, which 
have demonstrated the prognostic significance of comorbidities in many 
different types of cancer (Potosky et al., 2004; Earle et al. 2000; 
Extermann, 2000; Charlson et al., 1987; Tammemagi et al., 2004; Janssen-
Heijnen et al., 2004; Colinet et al., 2005; Birim et al., 2005; Imperatori et 
al., 2006; Asmis et al., 2008; Erridge et al., 2009; Grose et al., 2011). 
However the mechanism of comorbidity upon cancer outcome is not clear. 
In addition there are often significant differences between the methods 
used to document and grade the severity of comorbidity (Grose et al., 
2011) 
 
 
The most widely quoted tool to assess comorbidity is the Charlson 
Comorbidity Index (Charlson et al., 1987) (CCI). This was designed in 1987 
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and assigned 19 conditions with a weighting index of 1 – 6 in attempt to 
quantify the likelihood of impact upon survival. Data was acquired via 
patients being admitted with medical conditions to a Washington Hospital, 
USA. This tool was initially validated in breast cancer patients with 10-
year mortality as an endpoint. It has also been validated in predicting 
progression-free survival (Charlson et al., 1987) in a variety of diseases 
such as breast and prostate cancer. However limitations with using this 
tool for lung cancer patients include absence of some potentially relevant 
diseases such as pulmonary fibrosis, the weighting of HIV is probably now 
less significant due to improved treatment and the lack of grading of 
severity of the specific disease(s) (Charlson et al., 1987; Grose et al., 
2011) 
 
 
In addition to stage of disease (Detterbeck et al., 2009) it is clear that the 
prognosis in lung cancer is determined by more than just comorbidity. 
Performance status is widely recognised as a very accurate predictor of 
survival in cancer patient (Martin et al., 2010; Mor et al., 1984; Yates et 
al., 1980). Recent work shows that the effect of systemic inflammation is 
detrimental in terms of outcome in cancer in general (McMillan, 2009; 
Proctor et al., 2011) and in lung cancer specifically (Wilop et al.; Koch et 
al., 2009; Gagnon et al., 2010; Arrietta et al., 2010; Forrest et al., 2004; 
Forrest et al., 2005; Brown et al., 2007; Leung et al., 2012). The 
combination of C reactive protein and albumin when combined to 
calculate the modified Glasgow Prognostic Score has previously been 
validated as an independent predictor of survival (McMillan, 2013). Two 
recent publications by Laird et al., 2013 and Bozzetti et al, 2014 have 
demonstrated that a combination of mGPS and PS is predictive in 
determining survival in advanced cancer patients and it is likely that a 
common pathophysiological association between all these factors 
determines outcome. 
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We prospectively investigated the survival of a large unselected lung 
cancer population assessing the impact of comorbidity along with more 
standard prognostic determinants. The goal of this study was to determine 
the role of a novel comorbidity scoring system (SCSS) and to compare it 
with the already established Charlson Comorbidity Index and the modified 
Glasgow Prognostic Score (mGPS). We also wished to explore the 
relationship between comorbidity, mGPS and PS. In addition we 
investigated a number of standard prognostic markers and demographics. 
This study aimed to determine which of these factors provided the most 
accurate information on survival.  
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7.2 Methods 
 
Previously discussed in chapter 3 
 
 
 
7.3 Statistics 
 
All statistical testing was conducted at the 5% level so 95% confidence 
intervals (CI) are reported throughout.  Unless otherwise stated, medians 
and interquartile range (IQR) are used.  The survival time defined as the 
number of months from study entry until death or if alive at follow-up 
date, was calculated.  Univariate survival analysis was carried out using 
Kaplan-Meier method and the log rank test.  Survival analysis was carried 
out using the Cox’s proportional-hazards model and hazard ratios (HR) 
were calculated.  Multivariate survival analysis was performed using a 
stepwise backward procedure to derive a final model of the variables that 
had a significant independent relationship with survival.  To remove a 
variable from the multivariate model, the corresponding P-value had to be 
>0.20.  
 
 Statistical analyses were performed using SPSS v21.0 (SPSS Inc., Chicago, 
IL). 
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7.4 Results 
 
 In total, 882 patients from a number of different treatment groups were 
initially included in the study, comprising 297 from Aberdeen, 136 from 
Dunfermline, 285 from Glasgow, and 164 from Inverclyde.  Baseline 
characteristics are previously described in chapter 4.  The median age of 
participants was 72 years old. The majority of patients were male, current 
or ex-smokers, of good performance status with advanced disease and had 
treatment with palliative intent.  
 
The median follow up for survivors was 24.5 months (4.6 – 40.8).  The 
median overall survival was 5.6 months (4.8 – 6.5).  The 12-month survival 
rate was 30% (SE 2%). 
 
Impact of Comorbidity  
 
The cumulative comorbidity score, SCSS, was highly significant (p<0.001). 
Survival with low levels of comorbidity had a hazard ratio of 1.29 (1.02-
1.6) while for high levels of comorbidity it was 2.05 (1.55-2.70). The 
survival varied at 6 months from 60.2% for those patients with no 
comorbidity to 32.9% in those patients with high levels of comorbidity, 
while at 24 months the survival varied from 22.2% to 6.4%. In addition, the 
cumulative comorbidity score clearly increased as both PS and mGPS 
increased. These relationships are shown in Table 7.1 for the Early Stage 
group and Table 7.2 for the Advanced Stage group. 
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Table 7.1 – Median Cumulative Comorbidity Score (Range) as 
determined by PS and mGPS in the Early Stage group (Stage I-IIIa 
NSCLC). (no of patients). Missing data = 30 patients 
 
 
 
 
 
 
PS 
 
                                                    mGPS 
0 1 2 
 
 
0 
1(5) 
 
14 patients 
2.5 (3) 
 
6 patients 
3.5 (5) 
 
2 patients 
 
 
 
1 
3 (5) 
 
23 patients 
3 (9) 
 
26 patients 
2 (4) 
 
9 patients 
 
 
 
2 
3.5 (8) 
 
12 patients 
4 (9) 
 
18 patients 
3 (4) 
 
10 patients 
 
 
 
3 
- 3.5 (6) 
 
4 patients 
 
7 (0) 
 
2 patients 
 
 
4 
 
- - 9 (0) 
 
1 patients 
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Table 7.2 – Median Cumulative Comorbidity Score (Range) as 
determined by PS and mGPS in the Advanced Stage group. (no of 
patients). Missing data  = 135 patients 
 
 
 
 
 
 
PS 
 
                                                    mGPS 
0 1 2 
 
 
0 
1(10) 
 
27 patients 
1 (9) 
 
19 patients 
2 (1) 
 
3 patients 
 
 
 
1 
2 (7) 
 
63 patients 
3 (9) 
 
95 patients 
3 (10) 
 
36 patients 
 
 
 
2 
3 (9) 
 
42 patients 
4 (14) 
 
82 patients  
5 (13) 
 
70 patients 
 
 
 
3 
4 (10) 
 
17 patients 
4 (15) 
 
35 patients 
 
4 (12) 
 
52 patients 
 
 
4 
 
1 (5) 
 
3 patients 
3 (6) 
 
3 patients 
6 (13) 
 
17 patients 
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Early Stage group 
 
The relationship between the clinico-pathological characteristics and 
survival in patients with a Early Stage cancer is shown in Table 7.3. This 
group included patients with NSCLC Stage I – IIIa , the intention in such 
patients is for potential cure of cancer. Patients who were not offered a 
curative treatment were still included in this group. The median survival 
was 16.2 (11.7-20.7) months. On univariate survival analysis, age 
(p=0.009), sex (p<0.001), Performance status (p<0.001), SCSS (p=0.017), 
mGPS (p<0.001) and treatment (p<0.001) were significantly associated 
with survival. On multivariate analysis, only sex (p<0.001), SCSS (p=0.002), 
mGPS (p<0.001) and treatment (p<0.001) were independently associated 
with survival. 
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Table 7.3 – The relationship between parameters and survival in the Early Stage group 
(Stage I, II and IIIa NSCLC) (missing data refers to those without a survival endpoint) 
 
Parameter Patients Univariate           Multivariate 
 N HR (95%CI) p-value HR (95%CI) p-value 
Age (missing data = 10) Overall p =0.009 
<60 13 1    
60-69 56 1.54(0.79-2.99) 0.205   
70-79 60 2.09(1.09-4.00) 0.026   
≥80 18 3.23(1.62-6.43) <0.001   
Sex (missing data =9)  
Male 87 1 <0.001  <0.001 
Female 61 0.55(0.39-0.77)  0.32 (0.20-0.52)  
Centre (missing = 12) overall p=0.559 
      Aberdeen 59 1    
Dunfermline 27 1.22(0.77-1.96) 0.397   
     Glasgow 39 1.31(0.89-1.94) 0.175   
     Inverclyde 
 
23 1.24(0.75-2.05) 0.395   
Deprivation (Quintile) 
(missing =9) p =0.584 
  
 
Most 38 1    
2 25 0.69(0.42-1.15) 0.154   
3 43 0.76(0.49-1.16) 0.208   
4 31 0.76(0.47-1.20) 0.240   
Least 11 0.72(0.36-1.42) 0.341   
Smoking history (missing = 15) p=0.545 
NS 4 1    
<20 19 0.61(0.24-1.53) 0.290   
20-60 87 0.53(0.23-1.22) 0.135   
>60 32 0.59(0.25-1.43) 0.247   
Performance Status (missing 9) p<0.001 
0 33 1    
1 62 1.38(0.84-2.28) 0.207   
2 44 1.71(1.02-2.85) 0.041   
3 8 4.38(2.29-8.40) <0.001   
4 1 21.1(2.67-167) 0.004   
Scottish Comorbidity Score (missing = 10) 
p=0.017 
 
Nil 17 1   0.005 
Low (1-6) 113 1.89(0.92-3.92) 0.084 1.66 (0.73-3.78) 0.227 
High(7+) 17 3.66(1.54-8.66) 0.001 5.10 (1.84-14.1) 0.002 
Charleson Comorbidity Index missing =10 
Overall p =0.341 
 
Nil 38 1    
Low (1-2) 83 1.21(0.79-1.85) 0.391   
Mod (3-4) 23 1.45(0.87-2.41) 0.153   
High (>5) 
 
3 2.01(0.83-4.88) 0.121   
mGPS (missing =37) 
Overall p <0.001 
0 50 1   0.002 
1 49 1.70(1.12-2.58) 0.013 1.53 (0.92-2.54) 0.102 
2 21 2.82(1.60-4.99) 
 
<0.001 3.24 (1.70–6.15) <0.001 
Treatment (missing 9) Overall p <0.001 
Surgery 54 1   0.002 
Radical RT 29 1.61(0.92-2.81) 0.094 1.36 (0.70-2.66) 0.361 
Pall Chemo 9 1.93(0.91-4.11) 0.086 1.34 (0.58-3.08) 0.486 
Pall RT 18 3.86(2.06-7.23) <0.001 3.55 (1.77-7.10) <0.001 
BSC 38 2.43(1.44-4.09) 0.001 2.90 (1.49-5.66) 0.002 
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Advanced Stage group 
 
The relationship between the clinico-pathological characteristics and 
survival in patients with an Advanced Stage cancer is shown in Table 7.4. 
This group included patients with advanced NSCLC (Stage IIIB/IV) and SCLC 
where the intention of treatment is almost always palliative. The median 
survival was 4.1 (3.5-4.8) months. On univariate survival analysis, age 
(p<0.001), centre (p=0.003), PS (p<0.001), SCSS (p<0.001), mGPS 
(p<0.001), and treatment (p<0.001) were significantly associated with 
survival. On multivariate analysis, only PS (p<0.001) and mGPS (p<0.001) 
were independently associated with survival. 
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Table 7.4  – The relationship between parameters and survival in the Advanced Stage group 
(Stage IIIb/IV NSCLC, SCLC and not staged) (missing data refers to those without a survival 
endpoint) 
 
Parameter Patients Univariate           Multivariate 
 N HR (95%CI) p-value HR (95%CI) p-value 
Age (missing data = 25) Overall p <0.001 
<60 105 1    
60-69 171 1.27(0.98-1.63) 0.067   
70-79 238 1.39(1.09-1.77) 0.008   
≥80 114 1.79(1.36-2.36) <0.001   
Sex (missing data=24)  
Male 353 1 0.370   
Female 276 0.93(0.79-1.09)    
Centre (miss = 24) overall p=0.003 
      Aberdeen 225 1    
Dunfermline 92 1.52(1.18-1.94) 0.001   
      Glasgow 172 0.99(0.81-1.22) 0.938   
      Inverclyde 140 1.25(1.00-1.55) 0.046   
Deprivation (Quintile)  
(missing =24) p =0.545 
  
 
Most 184 1    
2 91 1.03(0.80-1.33) 0.820   
3 175 0.96(0.76-1.21) 0.633   
4 129 0.89(0.76-1.21) 0.737   
Least 50 0.80(0.58-1.11) 0.182   
Smoking history (missing = 61) p=0.902 
NS 37 1    
<20 60 1.11(0.73-1.69) 0.617   
20-60 359 1.00(0.71-1.41) 0.984   
>60 136 1.04(0.72-1.51) 0.824   
Performance Status (missing 24) p<0.001 
0 60 1  1 <0.001 
1 211 1.57(1.15-2.14) 0.004 1.70 (1.19-2.42) 0.004 
2 212 2.55(1.87-3.48) <0.001 2.57 (1.78-3.71) <0.001 
3 119 5.32(3.80-7.45) <0.001 5.03 (3.34-7.58) <0.001 
4 27 9.08(5.66-14.56) <0.001 8.71 (4.86-15.6) <0.001 
Scottish Comorbidity Score (missing = 35) 
p<0.001 
 
Nil 79 1    
Low (1-6) 430 1.33(1.03-1.72) 0.028   
High(7+) 109 1.93(1.43-2.62) <0.001   
Charleson Comorbidity Index missing =30. 
Overall p =0.271 
 
Nil 219 1    
Low (1-2) 294 0.99(0.83-1.19) 0.933   
Mod (3-4) 92 1.02(0.79-1.30) 0.901   
High (>5) 18 1.66(1.03-2.69) 0.039   
mGPS (missing =103) 
Overall p <0.001 
0 
 
148 1  1 <0.001 
1 227 1.60(1.28-1.98) <0.001 1.51 (1.21-1.89) <0.001 
2 175 2.39(1.90-3.01) <0.001 1.54 (1.20-1.99) 0.001 
Treatment (missing 24) Overall p <0.001 
Radical RT 41 1    
Pall Chemo 
 
224 1.65(1.15-2.36) 0.006   
Pall RT 
 
143 2.58(1.78-3.76) <0.001   
BSC 221 2.18(1.52-3.12) <0.001   
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6.5 DISCUSSION 
 
 
This large unselected population based cohort study of lung cancer 
patients has demonstrated that a number of important factors have 
significant impact in terms of survival. It has gone further by showing that 
the factors, which influence survival, are different, depending upon the 
stage of cancer at diagnosis and the potential treatment strategy. The 
novel comorbidity scoring system, the SCSS has compared very favourably 
with the more established CCI. In addition, it has confirmed the very poor, 
general outlook for lung cancer patients with a median survival of only 5.6 
months.  
 
Our results have shown that in those patients whose cancers can be 
considered radically treatable female sex, a normal mGPS, low levels of 
comorbidity based upon the SCSS and being offered surgery were all 
associated with better survival. Female sex and being offered surgery have 
both previously been demonstrated to improve outcome in localized NSCLC 
(Rich et al., 2011; NICE, 2011). Since the initial work, a decade ago the 
combination of C-reactive protein and albumin, the Glasgow Prognostic 
Score (GPS/ mGPS), has been shown to have independent prognostic value 
in more than 60 studies (>30,000 patients with cancer).  This prognostic 
value has been demonstrated in a variety of clinical scenarios, in 
particular primary operable cancer (McMillan, 2013; Grose et al., 2014). 
Comorbidity has often been identified as a cause of poor survival in lung 
cancer and the finding of the high levels of comorbidity and the impact 
upon survival of the SCSS is supported by many previous studies (Deleuran 
et al., 2013; Luchtenborg et al., 2012; Ahn et al., 2013). 
 
In those patients whose cancer was suitable only for palliative treatment 
options only a higher PS and elevated mGPS, indicating systemic 
inflammation, were associated with poorer outcome. Both of these have 
been demonstrated previously to have a significant impact upon outcome 
	   124	  
(Laird et al., 2013; Grose et al., 2014). The very poor outcome of the 
palliative patients, with a median survival of only 4.1 months, may be the 
reason why factors such as comorbidity did not appear to associated with 
survival. Even active palliative treatment such as chemotherapy did not 
appear to benefit survival across the population when other factors were 
accounted for in the multivariate analysis. Although chemotherapy has 
been shown to confer a survival benefit in large randomized trials (SIGN, 
2005; NICE, 2011), this is obviously in good PS patients with low levels of 
comorbidity and this paper supports most clinicians assertions that 
palliative chemotherapy should only be offered to the fitter group of 
patients with advanced lung cancer. 
 
It is perhaps surprising that the CCI was not associated with survival in 
either cohort. However several recent studies have also found no or little 
relationship (Wang et al., 2012; Ganti et al., 2011; Girones et al., 2011). 
The reason(s) for this are not particularly clear. However it is important to 
note that the CCI is now nearly 30 years old and its validation came 
primarily in a North American breast cancer cohort and thus may not be 
relevant to the Scottish lung cancer population. The weighting of some 
diseases e.g. AIDS, indicating the previous lack of treatment and poor 
survival, have significantly changed and it may be that novel scoring 
systems such as the one described above may have more validity in the 
current setting. 
 
In addition we have demonstrated a clear trend in rising comorbidity score 
as both PS and mGPS rise. As demonstrated above all three of these 
factors appear to be determinants in patient survival. This suggests that 
there is a complex relationship between such factors and to the best of 
our knowledge this relationship has not previously been demonstrated in 
the literature. One limitation of this current study is the lack of reason for 
the treatment offered. However we intend to address this in a future 
paper.  
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In conclusion we have identified that a variety of factors are independent 
prognostic determinants of outcome in lung cancer. There appear to be 
clear differences between the radical and palliative groups.  Especially in 
the select group of patients in whom cure of cancer is being attempted it 
is clear that a more detailed assessment of fitness including comorbidity 
and evidence of systemic inflammation is required before embarking upon 
a treatment plan. As the percentage of elderly patients who by definition 
may have more comorbidity increases then this will become even more 
important in the future. 
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CHAPTER 8: IMPACT OF THE TREATMENT DECISION 
PROCESS UPON SURVIVAL IN LUNG CANCER 
 
8.1 Introduction 
 
Lung cancer is the commonest cancer in Scotland and the second 
commonest in the UK (Office for National Statistics, 2006; ISD, 2009). 
Although one and two year survival has improved over the past decade, 
five year survival remains significantly poorer in Scotland than in 
comparable Western European countries or the USA, with 5-year relative 
survivals of 8.0%, 10.2% and 16.3%, respectively.  Variations in treatment 
may explain some of the observed differences in lung cancer survival 
between countries (Berrino et al., 2007; Horner et al., 2009). 
 
Treatment options are dependent upon pathology, TNM staging, patient 
fitness and choice. Radical (i.e. potentially curable) treatment options are 
surgery or radical radiotherapy (+/- chemotherapy). Patients with Stage I + 
II Non Small Cell Lung Cancer (NSCLC) should be considered for curative 
surgery whenever possible as it confers the highest chance of cure. 5 Year 
survival of 54-80% for patients with St 1a and 38-65% for patients with 
Stage 1b has been reported (Suzuki et al., 1999; Makitaro et al., 2002; 
Inoue et al., 1998). In patients with localized NSCLC not suitable for 
surgery then radical radiotherapy (+/- chemotherapy) is an appropriate 
option. Meta-analysis of retrospective studies in patients with Stage I/II 
has shown overall survival from 50-93% at one year and 0-42% at 5 years 
(Rowell et al., 2004). In recent years the option of Stereotactic Ablative 
Radiotherapy (SABR) has become a very reasonable alternative for those 
with early stage disease and in many centers’ has replaced conventional 
radiotherapy in this setting. (Palma et al., 2011; Lagerwald FJ, 2012) 
 
In patients with advanced disease and a Performance Status (PS) <2 then 
systemic chemotherapy with a platinum based doublet has been shown to 
confer a survival benefit of approximately 2 – 4 months (Goffin et al., 
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2010). Recent therapeutic advances including tyrosine kinase inhibitors (in 
those with an EGFR mutation) (Rosell et al., 2012) and 
pemetrexed/platinum doublets in Adenocarcinoma (Scagliotti et al., 2008) 
have conferred further improvement in survival but these treatments were 
not available at the time of this study. 
 
A significant proportion of lung cancer patients are not suitable for more 
aggressive therapies such as resection or radical radiotherapy in localized 
disease or indeed palliative chemotherapy in the more advanced setting 
(Grose et al., 2014; Grose et al., 2015; Havlik et al., 1994; NLCA 2013). 
Clearly this will significantly impact upon survival. Guidelines such as the 
National Institute for Clinical Excellence (NICE Guideline 121) and the 
Scottish Intercollegiate Guidelines Network (SIGN Guideline 137) have 
stated that a patient’s suitability for a particular treatment option should 
be based upon an assessment including fitness, comorbidity and PS and 
that options such as surgery or radical radiotherapy in the curative setting 
or chemotherapy in the palliative setting are only suitable for those with 
an adequate level of fitness and PS. 
 
Previous work undertaken by this group has supported the available 
guidelines in suggesting that PS, comorbidity and late stage at time of 
presentation all significantly impact upon survival (Grose et al., 2014; 
Grose et al., 2015). 
 
The purpose of this study was to determine the reasons for clinician’s 
decision-making process and if these reasons did indeed mirror the 
individual patient’s demographics, fitness and stage. We therefore 
evaluated demographics, PS and comorbidity in both the palliative and 
radically treatable patient groups. Our aim was to determine if treatment 
offered and the evidence available substantiated the reason for that 
treatment being offered. 
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8.2 Methods 
 
Previously discussed in chapter 3 
 
 
8.3 Statistics 
 
All statistical testing was conducted at the 5% level so 95% confidence 
intervals (CI) are reported throughout.  Unless otherwise stated, medians 
and interquartile range (IQR) are used.  The survival time defined as the 
number of months from study entry until death or if alive at follow-up 
date, was calculated.  Univariate survival analysis was carried out using 
Kaplan-Meier method and the log rank test.  
 
 
 
 
 Statistical analyses were performed using SPSS v21.0 (SPSS Inc., Chicago, 
IL). 
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8.4 Results 
 
 In total, 646 patients from a number of different treatment groups were 
initially included in the study, comprising 218 from Aberdeen, 91 from 
Dunfermline, 194 from Glasgow, and 143 from Inverclyde. Baseline 
characteristics are shown in Table 8.1.  The median age of participants 
was 70 years old. The majority of patients were male, current or ex-
smokers, of good performance status with advanced disease and had 
treatment with palliative intent.  
 
The median duration of follow up of survivors was 52.6 months (43.2 – 
58.9). The median overall survival was 6.1 months (95% CI 5.3 – 7.0). The 
12 months survival was 32% (SE 2). The median duration of follow up of 
survivors is significantly increase compared to in previous chapters due to 
updating of the survival data. 
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Table 8.1 Baseline characteristics of patients with lung cancer 
(n=646)  
 
  
Parameter  
  
Age  (years) 
 
Median 70.0 years (range 31-92) 
Sex   Male 
          Female 
377 (58.4%) 
269 (41.6%) 
 
Smoking (missing = 30) 
              Never smoker 
<20 Pack Years 
 20-60 Pack Years 
 > 60 Pack Years    
 
 
34 (5.3%) 
68 (10.5%) 
378 (58.5%) 
136 (21.1%) 
Centre  
 Aberdeen 218 (33.7 %) 
 Dunfermline 91   (14.1%) 
 Glasgow  194 (30.0%) 
 Inverclyde 143 (22.1%) 
 
Deprivation (Quintile)  
 
             Most deprived 197 (30.5%) 
 2.00 94    (14.6%) 
 3.00 183 (28.3%) 
 4.00 132 (20.4%) 
 Most affluent 40   (6.2%) 
 
Performance Status 
 
 0  87    (13.5%) 
 1  252 (39%) 
 2 204 (31.6%) 
 3 91   (14.1%) 
 4 12   (1.9%) 
Co morbidity Score (missing = 6) 
            Nil 
            Low 
            High 
 
83    (12.8%) 
466 (72.1%) 
91   (14.1%) 
Staging  
 NSCLC I  66 (10.2%) 
 NSCLC II 43 (6.7%) 
 NSCLC IIIa 48 (7.4%) 
 NSCLC IIIb 140 (21.7%) 
 NSCLC IV 234 (36.2%) 
  
 SCLC Limited 33 (5.1%) 
 SCLC Extensive 82 (12.7%) 
Treatment   
            Surgery 
             Radical Radiotherapy 
             Palliative Chemotherapy 
             Palliative Radiotherapy + BSC 
             Best Supportive Care (BSC) 
56    (8.7%) 
74    (11.5%) 
232  (35.9%) 
123  (19.0%) 
161  (24.9%) 
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Stage I –IIIa NSCLC 
 
156 patients in total were included in this group of whom a treatment 
decision is available for 148. 88 patients were offered radical treatment 
with either surgery or radical radiotherapy and 68 were deemed suitable 
for palliative treatment, which included chemotherapy, palliative 
radiotherapy and/or best supportive care (bsc). The median survival was 
29.9 months (95% CI 18.2-41.6) and 11.3 months (95% CI 5.9-16.6) 
respectively (P<0.001). 
 
For those patients not undergoing radical treatment the reasons as 
recorded at the MDT were assessed. These were then compared with the 
actual results, for example, in whom the PS was recorded as the reason 
for suboptimal therapy the actual breakdown of PS was shown. Some 
patients may have more than one reason recorded. 
 
In the group in which age was a determining factor all were over 70 with 
the vast majority (69.2%) being 80 or over. In the group in which PS was a 
factor only 11.1 % had a PS of 1, of the remainder 70.4% had a PS of 2 with 
22.5% being PS 3/4. In the group in who comorbidity was a determining 
factor 77.5% had low levels of comorbidity while 22.5% had high levels. In 
7 patients radical therapy was refused (Table 8.2). 
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Table 8.2 Breakdown of determining factors for sub-optimal therapy 
in Stage I-IIIa NSCLC.  
 
 
Note – Patients may have more than one reason for sub-optimal therapy. 
 
 
 
Reason given 
for Sub-
optimal 
treatment 
Number Actual  Grouping Number (%) 
 
Age 13  Age 70 - 79 4   (30.8%) 
   > 79 9   (69.2%) 
  
PS 27  PS 1 3   (11.1%) 
   2 19 (70.4%) 
   3 4   (18.8%) 
   4 1    (3.7%) 
  
Comorbidity 40  Comorbidity Low 31 (77.5%) 
   High 9    (22.5%) 
 
Patient 
refusal 
7     
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There was a statistically significant difference in age (p <0.001), PS 
(p<0.001) and comorbidity (p=0.006) between the group offered radical 
treatment and those offered palliative therapy with the palliative group 
being older, having a higher PS and more comorbidity (Table 8.3). 
Deprivation, as based upon the SIMD quintile, was not statistically 
significant (p=0.379).  
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Table 8.3 Comparison of factors between those being offered radical 
and palliative therapy in Stage I-IIIa NSCLC. (n =156)  
 
 
 
 Radical Treatment offered 
(N=88) 
Palliative treatment offered 
(N=68) 
 
 
P 
value 
Age group (%) 
missing=1 
<0.001 
<60 10 (11.4%) 4 (5.9%)  
60-69 38 (43.2%) 19 (27.9%)  
70-79 37 (42%) 28 (41.2%)  
>80 3 (3.4%) 
 
17 (25%)  
 
PS (%) 
 
<0.001 
0 27 (30.7%) 7 (10.1%)  
1 48 (54.5%) 19 (27.5%)  
2 11 (12.5%) 36 (52.2%)  
3 2 (2.3%) 6 (8,7%)  
4 0 1 (1.4%) 
 
 
 
Comorbidity (%) 
missing = 1 
 
0.006 
nil 13 (14.9%) 4 (5.8%)  
low 69 (79.3%) 53 (76.8%)  
high 
 
5 (5.7%) 12 (17.4%)  
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Stage IIIb/IV NSCLC + SCLC 
 
 
447 patients were included in this group. 447 patients had a treatment 
decision available. 222 patients were offered chemotherapy while 225 
were offered best supportive care (bsc) +/- palliative radiotherapy. The 
median survival was 6.4 months (95% CI 5.2-7.5) and 2.4 months (95% CI 
2.0 -2.9) respectively (P<0.001). 
 
In those patients who were deemed inappropriate for chemotherapy due 
to age the vast majority were over 80 (65.7%). In the group in which PS 
was a factor 55.2% had a PS of 3 or 4, 39.2% had a PS of 2 while 5.6% had a 
PS of 1. No patient had a PS of 0. For those patients in whom comorbidity 
was a determining factor 4.6% had no recorded comorbidity, 59.3% had 
low levels of co morbidity identified as a reason and 36.1% had high levels. 
16 patients refused palliative chemotherapy. (Table 8.4) 
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Table 8.4 Breakdown of determining factors for sub-optimal therapy 
in Stage IIIb/IV NSCLC + SCLC  
 
Note – Patients may have more than one reason for sub-optimal therapy. 
 
 
Reason given 
for Sub-
optimal 
treatment 
Number Actual  Grouping Number (%) 
 
Age 35 Age 60-69 1 (2.9%) 
   70 -79 11 (31.4%) 
 >79 23 (65.7%) 
   
PS 125  PS 1 7    (5.6%) 
   2 49 (39.2%) 
   3 58 (46.4%) 
   4 11 (8.8%) 
  
Comorbidity 108 Comorbidity Nil 5  (4.6%) 
   Low 64 (59.3%) 
 High 39 (36.1%) 
 
Patient 
refusal 
16    
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There was a statistically significant difference in age (p <0.001), PS 
(p<0.001) and comorbidity (p<0.001) between the group offered radical 
treatment and those offered palliative therapy with the palliative group 
being older, having a higher PS and more comorbidity (Table 8.5). 
Deprivation was again not statistically significant (p=0.368) 
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Table 8.5 Comparison of factors between those being offered 
chemotherapy and supportive care in Stage IIIb/IV NSCLC + SCLC. (n 
=447) 
 
 
 
 Chemotherapy offered 
 
(N=222) 
Supportive care (+/- palliative 
RT) offered 
(N=225) 
 
 
P 
value 
Age group (%) <0.001 
<60 53 (23.9%) 28 (12.4%)  
60-69 83 (37.4%) 52 (23.1%)  
70-79 71 (32%) 97 (43.1%)  
>80 
 
 
15 (6.8%) 48 (21.3%)  
 
PS (%) 
 
<0.001 
0 31 (14%) 13 (5.8%)  
1 109 (49.1%) 50 (22.2%)  
2 66 (29.7%) 84 (37.3%)  
3 16 (7.2%) 67 (29.8%)  
4 
 
0 11 (4.9%)  
 
Comorbidity (%) 
missing = 4 
 
<0.001 
nil 35 (15.9%) 22 (9.9%)  
low 165 (75%) 147 (65.9%)  
high 20 (9.1%) 54 (24.2%)  
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8.5 Discussion 
 
 
 
Survival in lung cancer remains very poor; our study population, in which 
the median survival is 6.1 months, confirms this. This is despite advances 
in surgical techniques, new radiotherapy options such as SABR and novel 
chemotherapy agents. In a significant number of patients the treatment 
options will be reduced due to poor fitness, PS, comorbidity and advanced 
stage at presentation. However a number of publications (Blum et al., 
2014; Forrest LF et al., 2014; Koshy et al., 2015) have suggested that 
treatment disparities are a complicated and multifactorial issue and that 
clinician selection bias may have at least some influence. There has also 
been a recent publication suggesting that social class / deprivation may 
also influence treatment choice (Forrest LF et al., 2014) but this has not 
been identified in our study. 
 
We wished to determine the clinician’s reason(s) for treatment offered 
and how that compared with the actual objective fitness, PS, comorbidity 
and age of the patients. 
 
We have shown that for the majority of patients, both in the early and 
advanced stage at presentation, the treatment decision appears to be 
appropriate given the recorded fitness, PS and comorbidity. However in a 
small but significant number of patients there did appear to be 
discrepancies between the clinician’s reasons for sub-optimal therapy and 
the recorded objective assessment of the patient in question. We 
identified low levels of comorbidity as a reason for not offering either 
radical treatment in the early stage group or chemotherapy in the 
advanced stage group.  A previous publication (Grose et al., 2015) 
undertaken by ourselves demonstrates that low levels of comorbidity has 
little impact upon survival and that only high levels of comorbidity 
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influence outcome significantly and it may be that clinicians are being 
unduly influenced by the clinically irrelevant comorbidity. 
 
 
It is not clear to what extent such potential under treatment will affect 
overall survival of this group of patients but as we are faced with the 
challenges of significant advances in therapy in an increasingly old 
population it is clear that more detailed objective assessment of patients 
is required to ensure that all are offered the most appropriate therapy. 
Significant work (Laird et al., 2013; McMillan. 2013) has been undertaken 
utilizing markers of systemic inflammation such as the modified Glasgow 
Prognostic Score (mGPS) along with PS to predict outcome and survival in 
advanced cancer including lung cancer and this has demonstrated 
additional prognostic benefits over more conventional assessments. Such 
tools together with our own extensive work in co morbidity should go some 
way to addressing this increasing challenge.  
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CHAPTER 9: CONCLUSION AND FUTURE WORK 
 
9.1 Conclusions 
 
The overall aim of the Thesis was to examine the impact of comorbidity in 
lung cancer, to attempt to quantify the extent and severity of comorbidity 
and to explore its relationship with treatment and survival. 
 
This work has demonstrated that it is possible to collect very detailed 
audit data on a large number of patients across several centres in Scotland 
in real time during the MDT process and to prospectively analyse survival 
data. 
 
During the course of this work, a number of other publications have 
explored the role of comorbidity upon outcome in Lung Cancer. A recent 
prospective observational study (Calvo-Espinos et al., 2015) showed lower 
survival rates among lung cancer patients with higher age-adjusted 
Charlson Comorbidity Index, although numbers were small (n=66).  A far 
larger population based cohort study of 5,683 patients captured using the 
Nebraska Cancer Registry demonstrated that the presence of comorbid 
conditions was associated with reduced survival, however it did not 
attempt to grade severity of the conditions (Islam et al., 2015). A specific 
study of SCLC patients utilizing the Netherlands Cancer Registry also 
supported the view that increased comorbidity had a negative prognostic 
effect on survival (Aarts et al, 2015). However a retrospective study in 
Denmark of 20,552 non-surgically treated patients from 2005 – 2011 
(Mellemgaard et al., 2015) appeared to show that comorbidity (utilizing 
the Charlson Comorbidity Index) had a limited effect upon survival. It is 
difficult to collect retrospective comorbidity data and the authors 
acknowledged this. This only serves to highlight the need for comorbidity 
assessment to be taken prospectively and at the time of diagnosis. 
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A further retrospective study utilizing the ACE -27 comorbidity scoring 
system in a variety of tumours including lung cancer, in patients 
undergoing radiotherapy, (Owen et al., 2014) demonstrated an association 
between increased comorbidity and reduced active treatment rates. Its 
main conclusion was that further tumour specific, validated tools would be 
beneficial. Two recent studies have made use of the extensive Danish Lung 
Cancer Registry to assess the role of the CCI. Iachina et al(2014) explored 
the impact of the CCI on survival in NSCLC in 3135 patients diagnosed in 
2010. It showed that higher levels of comorbidity were associated with 
reduced survival, however there was significant missing data, which the 
authors acknowledged, was related to the retrospective nature of the 
work. The second paper (Deleuran et al., 2013) was a population based 
cohort study from 2000 to 2011 including 9369 patients. It demonstrated a 
small but significant increase in survival over this time period except in 
those patients with high levels of comorbidity. The conclusion for this was 
that those patients with high levels of comorbidity are unlikely to be 
offered the newer treatment options such as doublet chemotherapy or 
radiotherapy due to poorer fitness.  The Simplified Comorbidity Score 
(SCS) had previously been discussed in the initial literature review in 
chapter 2. A recent paper by Ball et al (2013) retrospectively analysed 921 
lung cancer patients to assess the impact of the SCS on survival. However 
when age, PS and stage was taken into account the SCS had no additional 
effect upon survival. 
 
The link between comorbidity (utilizing the CCI), socio-economic status 
and outcome has been assessed in two recent papers. In the first 15,582 
patients in the South of England with Lung Cancer (Berglund et al., 2012) 
were retrospectively analysed. It was demonstrated that levels of 
comorbidity increased with poorer socioeconomic status. 29.6% of patients 
had high levels of comorbidity in the most deprived quintile vs 23.8% in 
the least deprived quintile (p<0.001). It also revealed an associated trend 
towards survival differences in these groups. The second paper by 
Woolhouse (2011) also highlighted the previously discussed differences 
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between the UK and the remainder of Europe with regards to lower levels 
of treatment and poorer outcomes and identified the need for further 
research to identify reasons for such differences. 
 
As can be seen from the above updated assessment of the literature there 
remains an unmet need for detailed research into comorbidity in lung 
cancer and its influence upon outcome. It has been clearly highlighted by 
much of the research that prospective work to validate a novel tool would 
be hugely beneficial. 
 
The results of the work presented in this Thesis have demonstrated the 
significant prevalence and severity of comorbidity through utilization of a 
novel comorbidity scoring system, the Scottish Comorbidity Scoring System 
(Grose et al., 2014). In addition it has shown that there appears to be a 
relationship with both treatment offered and survival, particularly in 
patients who have potentially curable lung cancer (Grose et al., 2014). 
 
During the course of this work there have been significant developments in 
our understanding of Lung Cancer. At the time of the work commencing 
NSCLC was seen as a single entity. However we now see this as several 
very specific sub-types with particular targeted mutations such as 
Epidermal Growth Factor (EGFR) and Anaplastic Lymphoma Kinase (ALK) 
with associated varying treatment options (Rosell et al., 2012; Solomon et 
al., 2014) leading to potentially different outcomes. Any future work 
would need to very take into account such advances.  
 
National data has demonstrated that a significant percentage of patients 
initially present as an emergency admission and that such patients have a 
poorer outcome (Rich et al., 2011). Unfortunately the data capture in this 
work did not include a breakdown of mode of presentation. This is a 
weakness of this work as there would be significant interest to explore if 
there are differences in comorbidity, socio-economic status, systemic 
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inflammation and outcomes between those patients who present as an 
emergency and those who are referred via primary care. 
 
As discussed in Chapter 6, there has been significant research recently 
undertaken both in cancer in general and lung cancer in particular 
exploring the role of systemic inflammation upon outcomes and survival 
(Scagliotti et al., 2008; Du Clos et al., 2004; Nozoe et al., 2000; Coussens 
et al., 2002; Abramovitch et al., 1999; Canna et al., 2008). 
 
 The prognostic value of the combination of CRP and albumin, the 
(modified) Glasgow Prognostic Score (McMillan, 2014) has been 
demonstrated across a large number of clinical scenarios including lung 
cancer. Initially this has been seen as a predictive marker of outcome. 
However several new studies of a novel targeted agent, Ruxolitinib which 
is a Janus Kinase Inhibitor, are exploring treating patients with evidence 
of systemic inflammation indicating a potential role for stratifying patients 
by mGPS (Hu et al., 2014). 
 
It is of interest that particularly in those patients undergoing radical 
treatment, both mGPS and SCSS appear to impact upon survival in a 
multivariate model suggesting they both play an important role in 
determining outcome (Grose et al., 2014).  
 
Previously the most widely used determinant of comorbidity was the 
Charlson Comorbidity Index (CCI) and it noteworthy that in this cohort it 
did not appear to have a statistically significant relationship with 
outcome. The reasons for this are not clear but as previously discussed the 
CCI is now almost 30 years old and treatment and prognosis of a number of 
the diseases has dramatically changed in this period. It is clear that an 
updated Comorbidity Scoring System taking account of these changes is 
required and this work has demonstrated that the SCSS is one such 
potential tool. 
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It is encouraging that within this population it appears that the majority of 
patients were offered appropriate treatment as per national guidelines. It 
is likely that the MDT provides a strong role in this and this work supports 
the assertion that all lung cancer patients should be discussed within a 
specialist MDT setting with access to both thoracic surgical and clinical 
oncology input to ensure that radically treatable patients are discussed 
with the relevant clinicians. 
 
Despite this the outcome for patients generally remains very poor.The 
median overall survival of 6.1 months (95% CI 5.3 – 7.0) and the 12 months 
survival of 32% are stark reminders to all clinicians treating this disease of 
the very poor outcome for the vast majority of patients and their family 
and carers. As has been shown in Chapter 8 a small but significant number 
of patients appear to have been offered potentially sub optimal therapy 
based perhaps upon inaccurate clinical assessments and this reinforces the 
necessity for development of new clinical tools to help in the decision 
making process. The SCSS has been validated within this clinical setting to 
be easily recordable and provide clinically meaningful prognostic 
information. It is likely that the combination of such a comorbidity tool 
along with PS, stage and assessment of systemic inflammation (mGPS) will 
in the future provide increasingly accurate assessment of patients to aid in 
the increasingly complex and challenging decision making process. 
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9.2 Utilisation of the Scottish Comorbidity Scoring System + Proposed 
Future Work 
 
 
The aim of the research leading to this Thesis was to examine the impact 
of comorbidity in lung cancer, to attempt to quantify the extent and 
severity of comorbidity and to explore its relationship with treatment and 
survival. In addition the development and validation of the novel 
comorbidity scoring system has the potential for usage in future research 
work.  
 
Three current and future research projects are utilizing and developing 
upon the work in this Thesis. 
 
The Scottish Lung Cancer Forum has carried out a prospective audit of 
comorbidity, inflammation and management in small cell lung cancer.  It 
is the hypothesis that there are differences in outcome and treatment 
delivered that occur between regions within the UK and also 
internationally. The hypothesis is that this may be due to variations in 
comorbidity, inflammation and demographics. This study has utilized both 
the data collection tool developed for this Thesis and the SCSS to analyse 
comorbidity. 
 
This International study involves 9 Centres from across Scotland, England 
and also Berlin in Germany.  Recruitment lasted from June 2009 until 
December 2012.  So far we have at least 2 year follow up on 
approximately 700 patients. Data analysis is currently ongoing with 
preliminary results being anticipated by late 2015. 
 
From the results of the research presented in this Thesis it is clear that a 
very detailed assessment of comorbidity such as the SCSS would not be 
practical or indeed useful in all newly diagnosed patients. However it 
appears to have significant merit particularly in those patients who are of 
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borderline fitness for radical treatment such as surgery or radical 
radiotherapy. In such patients a very detailed assessment of comorbidity 
may identify patients who would be suitable for active steps to try to 
improve their fitness to allow such treatments. I am already beginning 
work with two groups specifically investigating this premise. 
 
Professor Roma Maguire based at the University of Surrey School of Health 
Sciences has published extensively in Lung Cancer with her main interest 
being in attempting to link markers of the inflammatory response to 
patient outcomes and symptoms with the hypothesis that significant levels 
of inflammation may correspond to increasing burden of symptoms. We 
intend to analyse the relationship between symptoms, SCSS and mGPS. In 
those with high burdens of comorbidity and inflammation the intention is 
to develop focused supportive care interventions targeting the 
inflammatory response including pharmacological or non-pharmacological 
(e.g. exercise) along with interventions to reverse comorbidity whenever 
possible.  
 
Dr Jo Bowden is a Consultant Palliative Care Physician at Edinburgh 
University. Her proposed MD will be to explore the relationship between 
comorbidity, muscle wasting in lung cancer and to assess how this impacts 
on physical function, treatment completion and survival. She is in the 
planning stage of an epidemiological study using a database of patients 
diagnosed with lung cancer pre-2010 in Scotland. The Edinburgh Research 
Team have developed software that allows the quantification of muscle 
mass from patients' staging/follow-up CT scans and are looking to combine 
this with information about patients' cancer characteristics and comorbid 
illnesses.  
 
Her proposal will include body composition analysis from our patient 
database and to then combine this with our comorbidity, inflammation 
and survival data.  
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The hypothesis is that these findings will help to identify patients who are 
the best (or better at least) candidates for cachexia management - 
whether in anticipation of starting cancer-modifying treatment (a 
'prehabilitation' approach), alongside treatment or even in the no 
treatment group. 
 
As can be seen from the above collaborations there will be significant 
future work utilizing the work undertaken in this Thesis and it is hoped 
that both the improved understanding of the role of comorbidity and 
inflammation in lung cancer along with potential future interventions may 
improve the poor outcome currently seen in this disease. 
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APPENDIX 1: DATA COLLECTION PROFORMA 
Patient Details 
 
M / F    Age____ Postcode (1st part)______  Weight______ 
 
Home circumstances   Live alone/Independant 
    Requiring support from Partner/Family 
 
Current Performance Status 0 1 2 3 4 (circle) 
 
Where PS>0, what is deciding reason 
 
1 Effect of lung cancer (acute poor PS) 
 
2 General frailness / chronic comorbidity (chronic poor PS) 
 
3 Combination (acute on chronic poor PS) 
 
Relative estimate of PS 6 months prior to diagnosis____________ 
 
Creatinine_______  Albumin_______ CRP_________(if measured) 
 
FEV1_______ % Predicted__________ MRC Dyspnoea score- Grade______ 
 
 
Significant comorbidity (ie affecting PS or requiring treatment) 
 
 COPD   0  1  2  3 
 
 IHD   0  1  2  3 
 
 Heart failure  0  1  2  3 
 
 CVA   0  1  2  3 
  
Dementia  0  1  2  3 
 
 Diabetes Mellitus 0  1  2  3 
 
 Renal Failure 0  1  2  3 
 
 Other malignancy    0  1  2  3 
 
 Weight loss  0  1  2  3 
 
 PVD   0  1  2  3 
 
 Alcohol  0  1  2  3 
 Significant other 0  1  2  3 
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Smoking  _____________ pack years 
  
 
 
Staging CT performed   Yes    No 
 
 
 
MDT 
 
 
 Patient not discussed at MDT  yes  no 
 
 Patient discussed at MDT   yes  no 
   
 
Patient discussed at MDT     seen  not seen 
then seen at specialist clinic (within 2weeks)     
 
 
Please record staff present at MDT 
 
 
 Respiratory Physician   yes   no 
 Clinical Oncologist    yes   no 
 Thoracic Surgeon    yes   no 
 Radiologist     yes   no 
 Palliative care Physician   yes   no 
 Pathologist     yes   no 
 Specialist nurse    yes   no 
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Non-small cell lung cancer Stage I 
 
  Local symptoms  yes  no 
 
 Proposed for surgical resection 
 
  If not, reason? 
 
   Age 
   Poor PS 
Comorbidity 
   Patient refusal 
 
 Alternative treatment recommended 
 
  Radical radiotherapy 
   
  Chemotherapy + Radical radiotherapy 
 
  Chemotherapy 
 
  High dose palliative radiotherapy 
 
  Palliative radiotherapy 
 
  Specialist palliative care referral 
 
  Active supportive care 
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Non-small cell lung cancer   Stage II 
   
Local symptoms  yes  no 
 
 Proposed for surgical resection 
 
  If not, reason? 
 
   Age 
   Poor PS 
Comorbidity 
   Patient refusal 
  
Alternative treatment recommended 
 
  Radical radiotherapy 
   
  Chemotherapy + Radical radiotherapy 
 
  Chemotherapy 
 
  High dose palliative radiotherapy 
 
  Palliative radiotherapy 
 
  Specialist palliative care referral 
 
  Active supportive care 
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Non-small cell lung cancer    Stage IIIa 
   
Local symptoms   yes  no 
 
 Proposed for Radical treatment 
 
   Surgery       
   Radical radiotherapy     
   Chemotherapy + Radical radiotherapy    
   Induction chemotherapy     
 
  If not, reason? 
 
   Age 
   Poor PS 
   Comorbidity 
   Disease volume too great 
Patient refusal 
 
 
Alternative treatment recommended 
 
High dose palliative radiotherapy 
 
  Palliative radiotherapy 
 
Palliative chemotherapy 
 
Specialist palliative care referral 
 
Active supportive care 
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Non-small cell lung cancer   Stage IIIb 
   
 
Local symptoms   yes  no 
 
 Proposed for radical treatment 
 
   Radical radiotherapy 
 
   Chemotherapy + Radical radiotherapy  
 
   Induction chemotherapy 
 
  If not, reason? 
 
   Age 
   Poor PS 
Comorbidity 
Disease volume too great 
Patient refusal 
 
 
 Alternative treatment recommended 
 
High dose palliative radiotherapy 
 
Palliative radiotherapy 
 
  Palliative chemotherapy 
 
Specialist palliative care referral 
 
Active supportive care 
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Non-small cell lung cancer    Stage IV 
   
 
Local symptoms   yes  no 
 
 Proposed for chemotherapy  
 
  If not, reason? 
 
   Age 
   Poor PS 
Comorbidity 
Patient refusal 
 
 
Alternative treatment recommended 
 
High dose palliative radiotherapy 
 
Palliative radiotherapy 
 
  Biological treatment 
 
Specialist palliative care referral 
 
Active supportive care 
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Small cell lung cancer  Limited stage 
 
  Local symptoms  yes  no 
 
   
 Proposed for concurrent chemoradiotherapy 
    
 
 Proposed for initial combination chemotherapy 
    
 
  If not, reason? 
 
   Age 
   Poor PS 
Comorbidity 
   Patient refusal 
 
 
Alternative treatment recommended 
 
Single agent chemotherapy 
 
Palliative radiotherapy 
 
  Specialist palliative care referral 
 
  Active supportive care 
 
 
   
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
	   178	  
Small cell lung cancer  Extensive disease 
 
  Local symptoms   yes  no 
 
 Proposed for combination chemotherapy  
 
  If not, reason? 
 
   Age 
   Poor PS 
Comorbidity 
   Patient refusal 
 
 
Alternative treatment recommended 
 
Single agent chemotherapy 
 
Palliative radiotherapy 
 
  Specialist palliative care referral 
 
  Active supportive care 
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Clinical/radiographic diagnosis (no histology) 
 
Investigations 
 
Biopsy procedure attempted?   Yes   No 
 
If yes - procedure(s) attempted   Bronchoscopy 
      Percutaneous lung biopsy 
      Transbronchial lung biopsy 
      Mediastinoscopy 
VATS 
Neck node FNA/Biopsy 
If no, reason? 
 
   Age 
 
   Poor PS 
 
Comorbidity 
    
   Inaccessible 
 
   Patient refusal 
    
 
Clinical/radiological stage 
 
 T 
 
 N 
 
 M 
 
 Stage I IIa IIb IIIa IIIb IV 
 
 Unknown 
 
TreatmentRecommended   
 
Radical radiotherapy 
 
High dose palliative radiotherapy 
     
  Palliative radiotherapy 
 
Chemotherapy     
 
  Specialist palliative care referral 
 
Active supportive care 
